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ABSTRACT
Background: A growing number of epidemiological studies indicate that metabolic syndrome 
(MetS) and its associated features play a key role in the development of certain degenerative brain 
disorders, including Alzheimer’s disease and vascular dementia. Produced by several different 
medicinal plants, berberine is a bioactive alkaloid with a wide range of pharmacological effects, 
including antidiabetic effects. However, it is not clear whether berberine could prevent the 
development of dementia in association with diabetes. 
Objective: To give an overview of the therapeutic potential of berberine as a treatment for 
dementia associated with diabetes. 
Search strategy: Database searches A and B were conducted using PubMed and ScienceDirect. In 
search A, studies on berberine’s antidementia activities were identified using “berberine” and 
“dementia” as search terms. In search B, recent studies on berberine’s effects on diabetes were 
surveyed using “berberine” and “diabetes” as search terms.
Inclusion criteria: Clinical and preclinical studies that investigated berberine’s effects associated 
with MetS and cognitive dysfunction were included.
Data extraction and analysis: Data from studies were extracted by one author, and checked by a 
second; quality assessments were performed independently by two authors.
Results: In search A, 61 articles were identified, and 22 original research articles were selected. In 
search B, 458 articles were identified, of which 101 were deemed relevant and selected. Three 
duplicates were removed, and a total of 120 articles were reviewed for this study. The results 
demonstrate that berberine exerts beneficial effects directly in the brain: enhancing cholinergic 
neurotransmission, improving cerebral blood flow, protecting neurons from inflammation, limiting 
hyperphosphorylation of tau and facilitating β-amyloid peptide clearance. In addition, evidence is 
growing that berberine is effective against diabetes and associated disorders, such as atherosclerosis, 
cardiomyopathy, hypertension, hepatic steatosis, diabetic nephropathy, gut dysbiosis, retinopathy 
and neuropathy, suggesting indirect benefits for the prevention of dementia.
Conclusion: Berberine could impede the development of dementia via multiple mechanisms: 
preventing brain damages and enhancing cognition directly in the brain, and indirectly through 
alleviating risk factors such as metabolic dysfunction, and cardiovascular, kidney and liver diseases. 
This study provided evidence to support the value of berberine in the prevention of dementia 
associated with MetS.
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1. Introduction
Recent World Health Organization data indicate that the global incidence of diabetes is 
increasing— approximately 422 million adults were living with diabetes in 2014, compared to 108 
million in 1980 [1]. Consequently, the incidences of the various comorbidities linked to diabetes are 
also on the rise, including degenerative and functional brain disorders, such as Alzheimer’s disease 
(AD) and vascular dementia (VaD) [2,3]. VaD is a type of dementia associated with 
cerebrovascular dysfunctions. Type 2 diabetes mellitus (T2DM) is associated with cardiovascular 
and cerebrovascular disease, and vascular mechanism may underlie the cognitive decline in VaD 
[4]. AD is a progressive neurodegenerative disorder and the most common form of dementia. 
Although the etiology of AD is not fully understood, it is generally characterized by deposition of 
β-amyloid peptide (Aβ) and hyperphosphorylation of tau protein [4–6]. Aβ reduces both 
acetylcholine (ACh) uptake and release [7], and deficient cholinergic neurotransmission is likely to 
be involved in the AD symptomatology [8]. In fact, most currently available dementia medications 
are acetylcholinesterase (AChE) inhibitors; however, these drugs only provide relief of symptoms 
[9]. Importantly, T2DM causes insulin resistance in the brain, and dysfunctional insulin signaling is 
increasingly recognized in the etiology of AD. Studies have suggested a strong association between 
insulin signaling and Aβ metabolism [10]. Cerebral insulin resistance results in glycogen synthase 
kinase 3β (GSK3β) activation, which leads to increased Aβ production and tau phosphorylation 
[11,12], suggesting that dysfunctional insulin signaling or glucose metabolism in the brain could 
lead to the accumulation of Aβ and hyperphosphorylated tau. Indeed, the term “type 3 diabetes” is 
often used to characterize AD [13,14], given the close pathophysiological link between cerebral 
insulin resistance and oxidative stress and the histopathological lesions and cognitive impairment 
observed in AD [7,8,15,16].
Berberine is an isoquinoline alkaloid produced by several medicinal plant species, such as barberry 
(Berberis vulgaris L.), Indian barberry (B. aristata DC.), goldenseal (Hydrastis canadensis L.), 
Oregon grape (Mahonia aquifolium (Pursh) Nutt.), Chinese goldthread (Coptis chinensis Franch., C. 
japonica Makino., and C. teeta Wall.) and Amur cork tree (Phellodendron amurense Rupr.). 
Berberine-containing plants have historically been used to treat gastrointestinal complications such 
as diarrhea and dysentery [17,18], and berberine’s antimicrobial activity has been well-
characterized [17,19]. However, in recent years, the focus of berberine research has shifted towards 
potential therapeutic benefits in treating metabolic dysfunctions, such as T2DM, with data 
indicating glucose- and lipid-lowering effects [20,21]. Clinical evidence suggests that berberine 
significantly reduces fasting and postprandial plasma glucose, glycosylated hemoglobin A1c, serum 
cholesterol, triglycerides and low-density lipoprotein cholesterol (LDL-C) in T2DM patients 
[22,23]. Therapeutic benefits of berberine in treating T2DM and metabolic syndrome (MetS) have 
been reviewed previously [20,21,24]. In addition, preclinical evidence suggests that berberine has 
neuroprotective activities [25,26]. However, there is no comprehensive review to discuss the 
potential use of berberine as a treatment for dementia associated with metabolic dysfunctions. This 
paper reviews the current preclinical and clinical data on the effects of berberine, particularly 
focusing on cognitive dysfunctions associated with T2DM and its associated comorbidities, and 
discusses potential benefits and underlying mechanisms at the molecular level.
2. Methods
In order to perform a systematic review of studies reporting the effects of berberine on cognitive 
dysfunctions and diabetes, two searches (A and B) were conducted using PubMed 
(https://www.ncbi.nlm.nih.gov/pubmed) and ScienceDirect (https://www.sciencedirect.com/).
2.1. Information sources and Search strategy
2.1.1. Search A: berberine for dementia prevention
Studies of berberine’s effects on dementia were retrieved using the search terms “(berberine) AND 
(dementia)” in PubMed’s and ScienceDirect’s advanced search interfaces, returning articles 
between January 2000 and May 2019. 
2.1.2. Search B: berberine for diabetes intervention
To compile the currently available data on the effectiveness of berberine on diabetes and its 
comorbidities, advanced searches of PubMed and ScienceDirect databases were conducted, 
matching the search terms “(berberine) AND (diabetes)” in title, abstract and keywords. Articles 
published between January 2010 and May 2019 were included in the search.  
2.2. Study selection and data extraction
Initially, studies were screened for relevance based on the title and abstract. At this point, reviews, 
unrelated studies and works without available full text were excluded. The full texts of potential 
studies were assessed following the exclusion and inclusion criteria listed below.
Eligibility criteria: (1) articles published in any non-English language were excluded; (2) case 
reports were excluded; (3) studies using mixtures of several compounds, conjugates and crude 
extracts were excluded; (4) original studies in vivo, in vitro and clinical studies were included. The 
quality of included articles was evaluated by assessing the intervention methods, materials 
(including the source of berberine) and the usage of established experimental systems and protocols. 
The following data were extracted: publishing data, research question(s), study design, outcomes 
and conclusion. Data were extracted by one author, checked by a second; and quality assessments 
by two other authors were independently conducted.
2.3 Synthesis of results
Included reports were classified according to the major research questions (i.e., antidementia, 
antidiabetic, or comorbidities). Results were synthesized, focusing on the association between 
dementia and MetS. Meta-analysis was not appropriate, due to the highly variable research 
methodologies and outcome measures.
3. Results 
Database searches A and B identified research articles that addressed the therapeutic effects of 
berberine on dementia and diabetes, respectively. From search A, 65 articles (61 in PubMed and 4 
in ScienceDirect) were identified, and 22 articles were deemed appropriate for inclusion according 
to the selection criteria. Among those, 16 studies used nondiabetic models [27–42] (Table 1) and 6 
studies used diabetic models (Table 2). From search B, 458 (372 articles in PubMed and 86 articles 
in ScienceDirect) were identified and 101 articles met the selection criteria, of which 4 articles were 
in both A and B. Seven additional studies on diabetes-associated dementia were determined to be 
relevant. One article [43] was classified into both “studies used diabetic models” (Table 2) and 
“diabetes-associated dementia” (Tables 3–10); as it was relevant to both sections, a total of 13 
articles were finally in Table 2 [43–55] and 91 articles in Tables 3–10 [22,43,56–144]. Tables 3–10 
are categorized by eight groups according to the main topics of each study: (1) pancreatic 
dysfunction (Table 3), (2) vascular and adipose tissue dysfunction (Table 4), (3) liver dysfunction 
(Table 5), (4) kidney dysfunction (Table 6), (5) gut dysbiosis and intestinal dysfunction (Table 7), 
(6) retinopathy (Table 8), (7) neuropathy (Table 9), and (8) others (Table 10). An overview of the 
search and selection processes is summarized in Fig. 1. 
Table 1. Research articles studying the use of berberine to treat dementia in nondiabetic models.
First author 
(Year)
Dementia type Study design Intervention Effects of berberine Conclusion Reference
Aski ML 
(2018)
VaD In vivo: VaD model induced 
by chronic CCH in rats
Berberine 50 
mg/(kgd) for 2 
months (p.o.)
Attenuated CCH-induced spatial learning and memory deficit; reduced CCH-induced apoptosis in 
hippocampal CA1 and increased neuronal density.
Berberine protects the hippocampus against 






In vivo: heavy metal-induced 
AD model in rats; in silico: 
Docking
Berberine 50 
mg/(kgd) for 30 d 
(p.o.)
In vivo: protected learning and memory; reduced lipid peroxidation and NO; increased antioxidant 
levels (GSH, SOD, GST, and GPx); reduced serum and brain AChE and MAO; reduced serum 
inflammatory cytokines (TNF-, IL-1, IL-6, and IL-12); reduction of APP and tau in the brain; 
protected against neurodegeneration in hippocampal CA1. In silico: may inhibit AChE, COX-2 and 
TACE.
Berberine has beneficial effect for AD via 
anti-inflammatory/antioxidant mechanism.
[28]
He W (2017) Familial AD In vivo: APP/PS1 AD model 
mice
Berberine 50 or 100 
mg/(kgd) for 14 d 
(p.o.)
Mitigated cognitive impairment; inhibited tau phosphorylation in the hippocampus; reduced the 
expression of NF-B elements in the hippocampus; enhanced GSH antioxidant; reduced lipid 
peroxidation; inhibited neuroinflammation (CD45, GFAP, IL-1, TNF-).
Berberine attenuated cognitive deficits and 
limited tau hyperphosphorylation, possibly 
via NF-κB pathway inhibition, and 
reduction of oxidative stress and 
neuroinflammation.
[35]
Kim YJ (2017) Cholinergic 
signaling 
impairment
In vitro: AChE inhibition Berberine 2 µmol/L 80% AChE activity inhibition. Berberine may enhance cholinergic 







In vitro: glutamate-induced 
oxidative stress and apoptosis 
in PC12 and N2a
Pretreatment with 
berberine 50 
µmol/L for 2 h 
before glutamate 
exposure
Inhibited glutamate-induced cell death; reduced glutamate-induced intracellular ROS generation 
and MDA; increased GSH content and SOD activity; reduced glutamate-induced DNA damage; 
reduced caspase-3 cleavage and increased Bax/Bcl-2 ratio.
Berberine protects against glutamate-
induced neuronal injury by decreasing 




Familial AD In vivo: AD model (3 × Tg-
AD) in mice; in vitro: 3 × Tg-
AD primary hippocampal 
neurons
Berberine 50 or 100 
mg/(kgd) for 4 
months (p.o.)
In vivo: attenuated spatial learning deficits; improved short-term and long-term memory; enhanced 
autophagy in the hippocampus. In vitro: enhanced autophagy; reduced APP and BACE1; 
facilitated Aβ clearance via autophagy.
Berberine alleviates cognitive impairment 
via promotion of autophagy and facilitation 
of Aβ clearance.
[38]
Liu X (2014) Tauopathy In vitro: CA-induced axonal 
transport impairment and 
neuronal damage in N2a cells
Berberine 25 
µg/mL
Berberine’s effects in CA-induced neuronal damages: suppressed reduction of cell viability; 
reversed PP2A inactivation; attenuated hyperphosphorylation of tau; protected against NF axonal 
transport impairment and neurite outgrowth impairment; suppressed oxidative stress induction.
Berberine inhibited CA-induced PP2A 
activity modulation and oxidative stress, and 
reversed hyperphosphorylation of tau and 









In vivo: D-galactose-induced 
cognitive deficits and 
disrupted synaptic 
communication model in rats
Berberine 100 
mg/(kgd) for 7 
weeks (p.o.)
Berberine’s effects on D-galactose-induced damage: restored LTP deficits; rescued memory 
impairment; reversed synaptic plasticity marker activity-regulated cytoskeleton-associated protein 
(Arc/Arg3.1) reduction in the hippocampus.
Berberine rescued D-galactose-induced 
memory and synaptic impairment, possibly 
via recovering hippocampal Arc/Arg3.1 
expression, an effector immediate-early 




AChE and BChE 
inhibition
In vitro: AChE and BChE 
assay
None Dose-response relationship. IC50 of berberine: AChE, 2.2 µg/mL; BChE, 
116.7 µg/mL.
[41]
Jia L (2012) Inflammation in the 
brain
In vitro: Aβ-induced 
inflammatory response in 
microglia (murine primary 
and BV2)
Berberine 2.5 or 5 
µmol/L
Berberine’s effects in Aβ-induced microglial inflammation: suppressed IL-6 and monocyte 
chemotactic protein-1 expression in Aβ-treated microglia; suppressed COX-2 and iNOS induction; 
inhibited Aβ-induced NF-κB activation, ERK and p38 phosphorylation.
Berberine can suppress Aβ-induced 





AD In vivo: AD model in 
TgCRND8 mice; in vitro: 
N2a-SweAPP cells
In vivo: berberine 
25 or 100 mg/kg 
per day for 4 
months (p.o.); in 
vitro: berberine 20 
µmol/L
In vivo, berberine had actions in AD model: alleviated learning and memory deficits; reduced 
corticohippocampal Aβ plaque pathology; reduced Aβ peptide level in the brain; reduced 
microglial and astroglial activation in the brain; suppressed hyperphophorylation of APP, CTF, and 
tau levels; enhanced GSK3β inactivation (phospho-GSK3β) and Akt phosphorylation. In vitro: 
enhanced Akt and GSK3β phosphorylation; reduced phospho-APP, CTFs and phosphorylated tau, 
which was inhibited by PI3K inhibitor.
Berberine restored cognitive functions, 
reduced APP and tau phosphorylation, via 
PI3K/Akt/GSK3β pathway.
[29]
Ji HF (2012) Neurotransmission 
impairment
In silico: docking simulation 
(AChE, BChE, and MAO)
None None. Theoretical Kd (µmol/L): AChE: 0.66; 
BChE: 3.31; MAO-A: 105.2; MAO-B: 66.0.
[30]
Zhu F (2011) Aβ 40/42, BACE In vitro: HEK293 cells 
expressing mutant APP 
(Swedish mutation)
Berberine 1, 5, 10, 
20 µmol/L
In mutant APP expressing cells: reduced Aβ 40/42 generation and BACE expression, which were 
inhibited by U0126 (an antagonist of the ERK1/2 pathway).
Berberine suppresses Aβ40/42 generation 
by downregulating BACE via ERK1/2 
activation.
[31]
Yu CJ (2010) IDO-1 associated In vitro: recombinant human Berberine Inhibition of IDO-1 by berberine. IC50/rhIDO-1: 9.3 µmol/L; IC50/HEK293-hIDO-1: 7 µmol/L; Ki: Berberine is an uncompetitive, reversible [32]
with AD IDO-1 (rhIDO-1) inhibition 
assay; HEK293-hIDO-1
8 µmol/L; but the type of inhibition is noncompetitive. inhibitor of IDO-1, which may be relevant 
to therapeutic potential for AD.
Jung HA 
(2009)
AD In vitro: BACE1, AChE, and 
BChE inhibition assay; ROS 
and peroxynitrite inhibition 
assay
Berberine Inhibited AChE (IC50: 0.44 µmol/L) and BChE (IC50: 3.44 µmol/L), but did not inhibit BACE1; 
inhibited peroxynitrite generation (IC50: 23.06 µmol/L), but did not inhibit ROS generation.
Berberine and other berberine alkaloids may 
have anti-AD effects via inhibition of 
AChE, BChE and nitrosative stress.
[33]
Zhu F (2006) AD In vivo: Aβ (1–40)-induced 
spatial memory deficits in rat
Berberine 50 mg/kg 
for 14 d (p.o.)
Berberine’s effects in Aβ (1–40)-induced spatial memory deficits model: ameliorated Aβ (1–40)-
induced spatial memory deficit; enhanced Aβ (1–40)-induced IL-1β and iNOS expression in the 
hippocampus.
Berberine might be beneficial in AD; 
however it might exacerbate inflammation.
[34]
A: amyloid ; AChE: acetylcholinesterase; AD: Alzheimer’s disease; APP: amyloid precursor protein; BACE: -site amyloid precursor protein-cleaving enzyme; BChE: butyrylcholinesterase; CA: calyculin A; CCH: cerebral 
hypoperfusion; COX-2: cyclooxygenase-2; CTF: C-terminal fragment of APP; ERK: extracellular signal-regulated kinase; GFAP: glial fibrillary acidic protein; GPx: glutathione peroxidase; GSH: reduced glutathione; GSK3: 
glycogen synthase kinase 3 ; GST: glutathione S-transferase; IC50: half maximal inhibitory concentration; IDO: indoleamine 2, 3-dioxygenase; IL: interleukin; iNOS: inducible nitric oxide synthase; LTP: long-term potentiation; 
MAO: monoamine oxidase; MDA: malonaldehyde; NF: neurofilament; NF-κB: nuclear factor κB; NO: nitric oxide; PI3K: phosphoinositide 3-kinase; p.o.: per os; PP2A: protein phosphatase 2A; PS1: presenilin-1; ROS: reactive 
oxygen species; SOD: superoxide dismutase; TACE: tumor necrosis factor--converting enzyme; TNF: tumor necrosis factor; VaD: vascular dementia.
Table 2. Research articles studying the use of berberine to treat dementia in diabetic models.
First author 
(Year)
Dementia type Study design Intervention Effects of berberine Conclusion Reference
de Oliveira 
JS (2019)
Sporadic AD In vivo: ICV-STZ-
induced sporadic AD 
type dementia model 
in rats
Berberine 50 or 100 
mg/(kgd) for 20 d 
(p.o.)
Recovered recognition memory; prevented ROS generation and lipid peroxidation in the 
hippocampus; reduced protein carbonylation in the hippocampus and cerebral cortex; prevented 
reduction of aminolevulinic acid dehydratase activity (heme synthesis) in the cerebral cortex; 
prevented the reduction of antioxidants in the hippocampus and cerebral cortex.
Berberine is neuroprotective and preserves 
recognition memory via reduction of oxidative 
stress.
[48]
Yin S (2018) VaD In vivo: STZ-induced 




In vivo: berberine 
1.0 g/(kgd) for 8 
weeks (p.o.)
In vivo: improved short-term learning and memory and alleviated the impairment of spatial 
memory; increased posterior cerebral artery blood flow; suppressed hyperglycemia-induced 
ectopic expression of miR-133a in cerebral middle artery; upregulated GTPCH1 expression and 
BH4 in cerebral middle artery and serum NO; suppressed serum MDA. In vitro: suppressed HG-
induced miR-133a expression; recovered BH4 levels and NO generation.
Berberine alleviates cognitive impairment in 
diabetic mice via improving endothelial NO 




DE-induced dementia In vivo: DE in T2DM 
model mice (db/db)
Berberine 50 
mg/(kgd) for 10 
weeks (p.o.)
Reduced cognitive impairment; promoted lipid metabolism (lowered body weight, reduced TAG, 
TC and LDL-C); decreased fasting glucose (better insulin tolerance); protected hippocampal 
neurons and synapses; inhibited hippocampal inflammation (NF-κB, TNF-); reduced ER stress.
Berberine is protective against DE-induced 






metabolism in the brain 
associated with diabetes
In vivo: STZ-induced 




Restored body weight and improved blood and urine sugar levels; restored brain weight; restored 
GLUT1 and GLUT3 levels in the brain; restored insulin signaling molecules (IRS, phospho-PI3K 
and phospho-Akt1) in the brain.
Berberine modulates glucose metabolism in the 















Berberine’s effects in medial prefrontal cortex (mPFC) of diabetic model: did not change IR 
expression; suppressed upregulation of phosho-IRS; inhibited phospho-PI3K, phospho-Akt and 
phospho-GSK3β; suppressed NF-kB activation, and phospho-JNK, PKC, IL-18, IL-1β and TNF-α 
induction; upregulated GLUT3 and enhanced glucose-uptake in the brain; suppressed diabetes-
induced APP and Aβ formation; suppressed diabetes-induced BACE-1 upregulation; ameliorated 
fear memory deficit in diabetic rats.
Berberine inhibits inflammation and APP and Aβ 
formation in mPFC, thereby preventing cognitive 
dysfunction, possibly via inhibition of 
PI3K/Akt/GSK3β pathway, JNK, NF-kB and PKC. 




Sporadic AD In vivo: ICV-STZ-
induced sporadic AD-
like dementia model 
in rats
Berberine 50 or 100 
mg/(kgd) for 21 
days (p.o.)
Berberine’s effects in ICV-STZ-induced sporadic AD: ameliorated weight loss; inhibited spatial 
learning and memory deficits; suppressed anxiety; suppressed AChE-induction in the hippocampus 
and cerebral cortex; suppressed apoptosis induction in the hippocampus and cerebral cortex.
Berberine ameliorated learning/memory deficits 
and anxiety, possibly via suppression of AChE 




Brain damage associated 
with diabetes
In vivo: STZ-induced 
diabetic model in rats
Berberine 50 or 100 
mg/(kgd) for 8 
weeks (p.o.)
Berberine’s effects in STZ-induced diabetic model: alleviated weight loss and hyperglycemia; 
reduced lipid peroxidation and nitrite generation in the hippocampus; restored hippocampal SOD; 
suppressed astroglial activation in the hippocampus.
Berberine suppressed diabetes-induced reactive 






Oxidative stress in the 
brain
In vivo: STZ-induced 
diabetic model in 
mice
Berberine 100 
mg/(kgd) for 2 
weeks (p.o.)





Learning and memory 
impairments
In vivo: STZ-induced 
diabetes in rats
Berberine 50 and 
100 mg/(kgd) for 
12 weeks (p.o.)
Berberine improved short-term plasticity in the dentate gyrus of hippocampus. Berberine prevents diabetes-induced learning and 






Learning and memory 
impairments
In vivo: STZ-induced 
diabetes in rats
Berberine 100 
mg/(kgd) for 11 
weeks (p.o.)
Restored hippocampal synaptic plasticity (LTP); ameliorated learning and memory impairment; 
attenuated apoptosis of hippocampal CA1 neurons.
Berberine prevents diabetes-induced learning and 
memory defects by improving hippocampal LTP 






In vitro: HG-induced 
damage in neuronal 
cells (SH-SY5Y)
Berberine 1, 3 and 
10 µmol/L
Inhibited HG-induced apoptosis of neurons; inhibited HG-induced ROS generation; increased Bcl-
2; reduced HG-induced cytochrome c release; induced IGF-1 receptor; induced phosphorylation of 
Akt and GSK3; induced nuclear factor erythroid 2 and heme oxygenase-1 expression; restored 
NGF levels.
Berberine protects neurons from HG-induced 
oxidative stress and death, possibly via IGF-







In vivo: STZ-induced 
diabetic model in rats
Berberine 25-100 
mg/kg twice daily 
(50-200 mg/[kgd]) 
for 30 d (p.o.)
Lowered blood glucose; reduced oxidative stress in the hippocampus and cortex; reduced AChE 
activity in the hippocampus and cortex; improved cognitive performance (spatial memory).
Berberine inhibits diabetes-induced oxidative stress 





Neuroinflammation In vitro: microglia 
(BV-2)
Berberine 1, 3, 10 
µmol/L, 
pretreatment for 30 
min
Suppressed LPS-induced and IFN--induced iNOS, COX-2, IL-6, TNF-, and IL-1 upregulation; 
suppressed ERK phosphorylation; stimulated phosphorylation of AMPK signaling pathway. 
AMPK inhibitor (compound C) attenuated the effect of berberine.
Berberine inhibits neuroinflammation by 
suppressing microglial activation via activation of 
AMPK signaling.
[46]
A: amyloid ; AChE: acetylcholinesterase; AD: Alzheimer’s disease; AMPK: 5'-adenosine monophosphate-activated protein kinase; APP: amyloid precursor protein; BACE: -site amyloid precursor protein-cleaving enzyme; 
BH4: tetrahydrobiopterin; db/db: leptin receptor-deficient; CA: calyculin A; COX-2: cyclooxygenase-2; DE: diabetic encephalopathy; ER: endoplasmic reticulum; ERK: extracellular signal-regulated kinase; GLUT: glucose 
transporter; GSK3: glycogen synthase kinase 3 ; GTPCH1: GTP cyclohydrolase 1; HG: high glucose; ICV-STZ: intracerebroventricular injection of STZ; IFN: interferon; IGF-1: insulin-like growth factor-1; IL: interleukin; 
iNOS: inducible nitric oxide synthase; IR: insulin receptor; IRS: insulin receptor substrate; JNK: c-Jun N-terminal kinase; LDL-C: low-density lipoprotein cholesterol; LPS: lipopolysaccharide; LTP: long-term potentiation; MDA: 
malonaldehyde; NF-κB: nuclear factor κB; NGF: nerve growth factoer; NO: nitric oxide; PI3K: phosphoinositide 3-kinase; PKC: protein kinase C; p.o.: per os; ROS: reactive oxygen species; SOD: superoxide dismutase; STZ: 
streptozotocin; T2DM: type 2 diabetes mellitus; TAG: triacylglycerol; TC: total cholesterol; TNF: tumor necrosis factor; VaD: vascular dementia.
Table 3. Research articles studying the use of berberine to treat pancreatic dysfunction of diabetes.
First author (Year) Target Study design Intervention Effects of berberine Conclusion Reference
Jiang YY (2017) Pancreatic 
dysfunction 
In vivo: STZ-induced 
diabetic model in rats; 
in vitro: islet cell line 
(Rin-5F)
In vivo: berberine 250 mg/(kgd) for 
8 weeks (p.o.); in vitro: berberine 
100 µmol/L
In vivo: reduced FBG and GSP; alleviated insulin 
resistance; restored β-cell functions. In vitro: enhanced 
glucose-stimulated insulin release; did not inhibit fatty 
acid-induced apoptosis; induced PARP-1 expression.
Berberine is effective against diabetes via 







In vivo: STZ-induced 
diabetic model in rats
Berberine 50 mg/(kgd) for 45 d 
(p.o.)
Reduced blood glucose and HbA1c; restored plasma 
insulin and hemoglobin; suppressed lipid peroxidation 
and restored antioxidants; reduced pancreatic damage; 
reduced inflammatory mediators and increased anti-
apoptotic and anti-inflammatory factors.
Berberine is anti-hyperglycemic and 
pancreas-protective possibly via 
antioxidative and anti-inflammatory 
activities.
[140]
Chen DL (2017) Pancreatic 
dysfunction 
In vivo: STZ-induced 
diabetic model in mice; 
in vitro: β cell line 
(NIT-1) exposed to HG
Berberine 5mg/(kgd) for 3 weeks 
(i.p.)
In vivo: suppressed serum glucose, TC, TAG and 
MDA and restored insulin and SOD; suppressed miR-
106b and restored SIRT1 in islets. In vitro: suppressed 
HG-induced MDA and restored insulin and SOD; 
suppressed HG-induced miR-106b and restored 
SIRT1.
Berberine restores insulin and suppresses 
hyperglycemia possibly via modulating 
miR-106b/SIRT1 pathway in pancreatic 
islets.
[141]





In vitro: insulinoma cell 
line (INS-1E) and 
pancreatic islets isolated 
from rat and mouse
In vitro: berberine 5 µmol/L Berberine’s effects in INS-1E exposed to HG: restored 
antioxidant (SOD); attenuated nitrosative stress 
(nitrotyrosine); restored phospho-AMPK; restored 
UCP2 expression; reduced mitochondrial ROS via 
AMPK signaling and restoration of UCP2; restored 
glucose-stimulated insulin secretion via AMPK 
signaling and restoration of UCP2. Berberine’s effects 
in isolated islets: restored phosho-AMPK in rats and 
mice; suppressed nitrosative stress via UCP2, and 
induced SOD in rats and db/db mice; restored insulin 
secretion via UCP2 in rats and db/db mice.
Berberine inhibited oxidative and nitrosative 
stress and restored insulin secretion in HG-
exposed islets via activation of AMPK and 
UCP2.
[142]
Shen N (2012) Pancreatic 
dysfunction
In vitro: mouse β-cell 
line (NIT-1) exposed to 
HG; in vivo: HFD-
induced obesity in mice
In vitro: berberine 1 µmol/L; in 
vivo: berberine 50 mg/(kgd) for 10 
weeks (p.o.)
In vitro: suppressed HG-induced insulin gene 
expression in β-cells via AMPK activation. In vivo: 
improved insulin resistance and glucose tolerance; 
decreased insulin in pancreatic islets.
Berberine may prevent diabetes by 
inhibiting insulin expression in β-cells via 
AMPK activation.
[139]
Chueh WH (2012) Pancreatic 
dysfunction
In vitro: STZ-treated 
primary pancreatic islet 
cells from mice 
In vitro: berberine 1 and 3 µmol/L Reduced cell death; pre-treatment can reduce the 
increase in Bax/Bcl-2 gene expression ratio.
Berberine may protect pancreatic islets via 
decreasing Bax/Bcl-2 ratio thereby inhibiting 
apoptosis.
[138]
Chueh WH (2011) Pancreatic 
dysfunction
In vivo: nonobese 
diabetic model in mice
Berberine 50, 150, and 500 
mg/(kgd) for 14 weeks (p.o.)
Restored pancreatic islets and serum insulin levels. Berberine protects pancreatic islets. [137]
ADP: adenosine diphosphate; AMPK: 5'-adenosine monophosphate-activated protein kinase; FBG: fasting blood glucose; GSP: glycated serum protein; HbA1c: glycosylated hemoglobin A1c; HFD: high-fat diet; HG: high glucose; 
i.p.: intraperitoneal injection; MDA: malonaldehyde; PARP-1: ADP-ribose polymerase; p.o.: per os; ROS: reactive oxygen species; SIRT1: sirtuin 1; SOD: superoxide dismutase; STZ: streptozotocin; TAG: triacylglycerol; TC: total 
cholesterol; UCP: uncoupling protein.




Target Study design Intervention Effects of berberine Conclusion Reference
Hirai T 
(2019)
Obesity & BAT In vitro: adipocytes (C3H10T1/2), 
primary white, brown, and beige 
adipocytes from mice
In vivo: HFD-induced obesity in 
mice
In vitro: berberine 3 and 10 
µmol/L
In vivo: berberine 10 
mg/(kgd) for 2 weeks (i.p.)
In vitro: induced FGF21 expression in brown adipocytes; induced 
Bmal1 expression in brown and beige adipocytes; enhanced AMPK 
phosphorylation. In vivo: restored Fgf21 mRNA expression in BAT, 
which was reduced by HFD; reduced body weight under HFD.
Berberine may induce adipocyte browning by 
inducing FGF21 via AMPK signaling and modulate 
Bmal1 (molecular clock), which may contribute to 





Atherosclerosis Clinical: patients undergoing PCI 
for ACS (n45); in vitro: ox-LDL-
induced macrophage activation
Clinical: berberine-treatment 
group, berberine 300 mg, 3 
times a day, in addition to 
standard therapy, for 3 
months; control group, 
standard therapy 
(clopidogrel, aspirin and 
rosuvastatin); in vitro: 
berberine 25 µmol/L
Clinical: no significant difference between berberine plus standard 
therapy and standard therapy alone in plasma Gal-3, serum lipids and 
inflammatory markers. In vitro, berberine’s effects on ox-LDL-
induced responses in macrophages: suppressed Gal-3 expression 
(overexpression of Gal-3 intervened the inhibitory effect of berberine 
on macrophage activation), inflammatory cytokines (IL-6, TNF-α and 
IL-1β), and CD86+/CD11b+ cells (%); induced AMPK 
phosphorylation and inhibited ox-LDL-induced p65 phosphorylation 
(AMPK inhibitor [compound C] abolished the effects of berberine).
Clinical: berberine has no additional benefit to 
standard therapy. In vitro: berberine alone alleviates 
ox-LDL-induced inflammatory responses via Gal-3 





Platelet hyperreactivity In vitro: human platelets
thrombin- and collagen-induced 
aggregation model, exposed to 
HG
Berberine 25 and 50 µmol/L Inhibited HG-potentiated platelet aggregation; inhibited mitochondrial 
membrane potential depolarization, ROS generation in HG-treated 
platelets, cardiolipin peroxidation, and restored cell viability; inhibited 
HG-induced ERK, pI3K, p38 and p53 phosphorylation, cytochrome c 
release, MPTP, and caspase-3 activation; inhibited glutathione 
reductase, aldose reductase and NOX; inhibited thrombin-induced 
ATP release.
Berberine attenuates HG-primed platelet aggregation, 
possibly via attenuation of ROS-mediated p38-p53 






In vitro: HG-induced 
hyperglycemia and cardiomyocyte 
hypertrophy model in H9C2 cell 
line
Berberine 100 nmol/L Attenuated HG-induced hypertrophy; protected mitochondria from 
HG-induced dysfunction (reduced ATP generation and MMP 
disruption); restored balance of mitochondrial fission/fusion; restored 
PGC-1α expression, mitogenesis and mitochondrial content; 
suppressed HG-induced mitophagy and mTOR activity; restored LC3 
and Beclin 1 expression and phospho-AMPK.
Berberine ameliorates HG-induced cardiomyocyte 







In vivo: HFD-induced metabolic 
dysfunction in mice
Berberine 100, 200, and 300 
mg/kg for 8 weeks (p.o.)
Reduced body weight and blood glucose and enhanced glucose 
tolerance; inhibited adipose tissue fibrosis and ECM secretion in 
eWAT; suppressed HIF-1α and LOX expression and inhibited 
adipocyte apoptosis in eWAT.






(associated with gut 
dysbiosis)
In vivo: atherosclerosis model 
mice (ApoE-/- mice fed with high 
fat diet HFD)
Berberine 50 mg/kg for 12 
weeks (p.o.); cohousing with 
berberine-treated mice
Berberine and cohousing: attenuated HFD-induced atherosclerosis; 
reduced HFD-induced inflammatory response.





Diabetic cardiac fibrosis In vivo: STZ and HFD-induced 
type 2 diabetic model in rats; in 
vitro: cardiac fibroblasts exposed 
to HG
In vivo: berberine 200 
mg/(kgd) for 4 weeks (p.o.); 
in vitro: berberine 50 µmol/L
In vivo: ameliorated hyperglycemia and hyperlipidemia and improved 
glucose tolerance; attenuated cardiac fibrosis and dysfunction; 
reduced cardiac IGF-1 receptor expression, as well as α-SMA, TGF-β, 
FN and collagen type I expression. In vitro: inhibited HG-induced 
hyperproliferation, expression of α-SMA and collagen type I; reduced 
expression levels of MMP-2/9/14, and IGF-1R and phospho-ERK1/2 
levels.
Long-term berberine treatment ameliorates cardiac 
fibrosis by downregulating IGF-1R expression, and 






In vivo: HFD-induced insulin 
resistance in mice; in vitro: SVF
In vivo: berberine 75 and 150 
mg/(kgd) for 4 weeks (p.o.); 
in vitro: berberine 10 µmol/L
In vivo: reduced serum insulin, FA and fat mass, and alleviated HFD-
induced insulin resistance and glucose intolerance; suppressed HFD-
induced expression of fibrogenic genes and MMP-9 and TIMP-1 
proteins, and alleviated ECM abnormality; recovered phospho-AMPK 
and phospho-ACC and downregulated TGF-β1 and phospho-Smad3 
in adipose tissue; suppressed HFD-induced increase in M1 
(inflammatory) macrophages in adipose tissue. In vitro: inhibited 
TGF-β1-induced phospho-Smad3; inhibited TGF-β1-induced 
expression of fibrogenic genes; inhibited TGF-β1 signaling only 
partly via phospho-AMPK.
Berberine inhibits aberrant ECM deposition, 
macrophage infiltration and M1 polarization in 
adipose tissue, possibly via inducing phospho-AMPK 




Atherosclerosis HFD-induced atherosclerosis 
model in ApoE-/- mice
Berberine in drinking water 
(0.5 g/L) for 14 weeks 
Alleviated atherosclerosis; suppressed hypercholesterolemia and 
systemic inflammation; prevented inflammation in the arterial tissues.
Berberine alleviates atherosclerosis via inhibiting 




Heart diseases In vitro: cardiac myocytes (H9c2) Berberine 6.25–25 µmol/L Inhibited oxygen consumption and DNA synthesis; reduced 
cardiolipin synthesis from oleic acid and increased cardiolipin 
synthesis from palmitic acid; inhibited PKCδ activation.
Berberine inhibits the growth of cardiomyocytes and 
oxygen consumption and altered cardiolipin 




Hypertension In vivo: STZ-induced diabetic 
model in rats
Berberine 100 and 200 
mg/(kgd) for 8 weeks (p.o.)
Ameliorated hyperglycemia and hypertension; improved endothelium-
dependent/independent relaxation in middle cerebral arteries in 
diabetes; restored the large-conductance Ca2+-activated K+ channel 
activity and β1 subunit expression.
Berberine helps control hyperglycemia and 







In vivo: HHCY model, ApoE-/- 
mice fed with HTL; ex vivo: HTL-
exposure of organ culture of aortic 
ring isolated from the descending 
aorta of mice; in vitro: HUVECs 
exposed to HTL
In vivo: berberine 1.0 
g/(kgd) for 4 or 8 weeks 
(p.o.); ex vivo: berberine 10, 
50, 100 µmol/L; in vitro: 
berberine 10, 50, 100 µmol/L
In vivo: berberine (4 weeks) enhanced the stability of atherosclerotic 
plaque and berberine (8 weeks) reduced restored NO and suppressed 
MDA levels in the blood; berberine (8 weeks) restored endothelial 
function. Ex vivo: restored endothelial function (ACh-induced 
vascular relaxation) via PPARγ; restored SOD activity and suppressed 
MDA levels via PPARγ. In vitro: berberine restored cell viability and 
reduced ROS, which were dependent on PPARγ.
Berberine enhances atherosclerotic plaque stability in 
hyperhomocysteinemia, via PPARγ activation and 







STZ and Isoproterenol-induced 
diabetes co-existing with 
myocardial infarction in rats
Berberine (100 mg/[kgd]) 
for 30 d (p.o.)
Restored body weight and improved blood glucose, HbA1c, TC, 
TAG, HDL-C, and LDL-C; protected myocardium, as well as other 
tissues (pancreas, liver, and kidney).





Vascular dysfunction In vivo: HFD and STZ-induced 
diabetic model in rats; in vitro: 
cerebral VSMCs
Berberine 100 mg/(kgd) for 
8 weeks (p.o.)
In vivo & in vitro: restored body weight, and reduced blood glucose 
and insulin; inhibited the contractile response of VSMCs; inhibited L-
type Ca2+ channel current.
Berberine alleviates the cerebral arterial contractility 
induced by diabetes via regulating intracellular Ca2+ 







In vivo: STZ and HFD-induced 
diabetic model in rats; ex vivo: 
mesenteric artery rings isolated 
from control and diabetic mice; in 
vitro: human artery endothelial 
cell line (EA.hy926), exposed to 
HG and palmitate
In vivo: berberine 200 
mg/(kgd) for 4 weeks (p.o.); 
ex vivo: berberine 200 
mg/(kgd) for 4 weeks (p.o.) 
or berberine 10 µmol/L; in 
vitro: berberine 50 µmol/L
In vivo: improved glucose tolerance. Ex vivo: improved ACh-induced 
vasodilation, which was inhibited by PI3K/Akt inhibitor 
(wortmannin). Berberine + insulin directly alleviated vascular 
dysfunction of mesenteric artery rings isolated from diabetic rats. In 
vitro: increased cell viability and autophagy in HG/HF-treated 
endothelial cells; upregulated phosphorylation of AMPK, Akt and 
eNOS, which was blunted in IR knock-down.
Berberine improves vascular functions by protecting 
endothelial cells from HG/HF-induced stress via 







In vivo: ischemia-reperfusion in 
STZ and HFD-induced diabetic 
model in rat.
Berberine 100 mg/(kgd) for 
7 d before heart perfusion
Berberine pretreatment: reduced TAG, TC and MDA, but did not alter 
blood glucose and SOD levels; reduced arrhythmias; increased the 
ratio of AMP/ATP and ADP/ATP; increased AMPK activity, as well 
as phospho-Akt and phospho-GSK3β.
Berberine is cardioprotective via activation of AMPK 




Insulin resistance of 
cardiomyocytes
In vitro: Palmitate-mediated 
insulin resistance model in 
cardiomyocytes (H9c2).
Berberine 12.5 µmol/L Restored glucose uptake and GLUT4 expression in the presence of 
palmitate; restored the level of phospho-Akt in the presence of 
palmitate; enhanced TAG accumulation but inhibited palmitate-
induced DAG accumulation in the presence of palmitate; enhanced 
palmitate-induced glucose incorporation into TAG and inhibited 
palmitate-induced glucose incorporation into DAG and cholesterol.
Berberine attenuates palmitate-induced reduction of 





Obesity (adipogenesis) In vitro: Adipocyte differentiation 
model (3T3-L1 cell line)
Berberine 5 µmol/L Suppressed the expression of adipogenic genes and induced phospho-
AMPK; suppressed CREB activation, CCAAT/enhancer-binding 
protein β (C/EBP-β) expression and CRE activity.





Obesity (adipogenesis) In vitro: Adipocyte differentiation 
model (3T3-L1)
Berberine 12.5, 25 and 50 
µmol/L
Reduced lipid accumulation; reduced C/EBP-α expression. Berberine inhibits lipid accumulation in adipocytes 




Cardiomyopathy In vivo: myocardial I/R injury in 
STZ and HFD-induced diabetic 
model in rats
In vitro: Primary neonatal rat 
cardiomyocytes in culture
In vivo: berberine 100, 200 
and 400 mg/(kgd) for 4 
weeks (p.o.) before I/R
In vitro: Berberine 50 µmol/L
In vivo: enhanced the recovery of cardiac systolic/diastolic function; 
reduced myocardial apoptosis. In vitro: reduced 
hypoxia/reoxygenation-induced myocardial apoptosis; enhanced 
AMPK activity, PI3K-Akt activation and eNOS phosphorylation. 
Pretreatment with PI3K-Akt inhibitor (wortmannin) or AMPK 
inhibitor (compound C) blunted the anti-apoptotic effect of berberine.
Berberine exerts anti-apoptotic effect and improves 
cardiac functional recovery after myocardial I/R via 




Endothelial dysfunction In vitro: Endothelial cell line 
(HUVECs) exposed to palmitate
Berberine 5 µmol/L Suppressed NO and ROS production; restored eNOS levels and 
suppressed NOX4 induction.
Berberine ameliorates palmitate-induced endothelial 







In vitro: HGI-induced 
cardiomyocyte hypertrophy.
Berberine 3 µmol/L Berberine suppressed HGI-induced cardiomyocyte hypertrophy, 
which was reversed in the presence of PPAR inhibitor; HGI 
Berberine can ameliorate HGI-induced 




inhibited PPAR expression, which was restored by berberine; HGI 





Ischemic arrhythmias In vivo: STZ-induced diabetic 
model in rats
Berberine 100 mg/(kgd) 
(p.o.) for 7 days before 
ischemia
Suppressed ischemia-induced arrhythmias in diabetic rats; suppressed 
abnormal prolongation of corrected QT interval; restored transient 
outward K+ current and L-type Ca2+ current.
Berberine is protective against cardiac arrhythmias 





(visceral WAT insulin 
resistance)
In vivo: HFD and STZ-induced 
type 2 diabetic model in hamsters
Berberine 150 mg/(kgd) for 
9 weeks (p.o.)
Reduced visceral WAT weight; restored the expression of LXRs and 
PPARs; suppressed SREBP induction.
Berberine improved visceral white adipose insulin 







In vivo: HFD and STZ-induced 
type 2 diabetic model 
with/without experimental 
myocardial infarction in rats
Berberine 180 mg/(kgd) for 
14 d (p.o.)
Suppressed arrhythmia; improved the resting membrane potential and 
current density; restored Kir2.1 (inward-rectifier K+ channel) 
expression in isolated ventricular myocytes.
Berberine suppresses arrhythmia in diabetes via 
restoration of K+ channel expression.
[110]
ACC: acetyl-CoA carboxylase; ACh: acetylcholine; ACS: acute coronary syndrome; ADP: adenosine diphosphate; AMP: adenosine monophosphate; AMPK: 5'-adenosine monophosphate-activated protein kinase; ATP: adenosine 
triphosphate; BAT: brown adipose tissue; CRE: cAMP-response element; CREB: cAMP-response element-binding protein; DAG: diacylglycerol; ECM: extracellular matrix; eNOS: endothelial nitric oxide synthase; ERK: 
extracellular signal-regulated kinase; eWAT: epididymal white adipose tissue; FA: folic acid; FGF21: fibroblast growth factor 21; FN: fibronectin; GLUT: glucose transporter; GSK3: glycogen synthase kinase 3 ; HbA1c: 
glycosylated hemoglobin A1c; HDL-C: high-density lipoprotein cholesterol; HF: high fat; HFD: high-fat diet; HG: high glucose; HGI: HG and insulin; HHCY: hyperhomocysteinemia; HIF-1: hypoxia-inducible factor 1; HTL: 
homocysteine thiolactone; HUVEC: human umbilical vein endothelial cells; IGF-1: insulin-like growth factor-1; IL: interleukin; i.p.: intraperitoneal injection; I/R: ischemia/reperfusion; IR: insulin receptor; LDL: low-density 
lipoprotein; LDL-C: low-density lipoprotein cholesterol; LOX: lipoxygenase; LXR: liver X receptor; MDA: malonaldehyde; MMP: matrix metallopeptidase; MPTP: mitochondrial permeable transition pore; mTOR: mammalian 
target of rapamycin; NF-κB: nuclear factor κB; NO: nitric oxide; NOX: nicotinamide adenine dinucleotide phosphate oxidase; PCI: percutaneous coronary intervention; PGC-1α: peroxisome proliferator-activated receptor gamma 
coactivator 1-α; PI3K: phosphoinositide 3-kinase; PKCδ: protein kinase Cδ; p.o.: per os; PPAR: peroxisome proliferator-activated receptor; ROS: reactive oxygen species; SMA: smooth muscle actin; SOD: superoxide dismutase; 
SREBP: sterol regulatory element-binding protein; STZ: streptozotocin; SVF: stromal vascular fraction; T2DM: type 2 diabetes mellitus; TAG: triacylglycerol; TC: total cholesterol; TGF-β: transforming growth factor-β; TIMP: 
tissue inhibitor of the matrix metalloproteinase; TNF: tumor necrosis factor; VSMC: vascular smooth muscle cells; WAT: white adipose tissue.
Table 5. Research articles studying the use of berberine to treat liver dysfunction of diabetes.
First author (Year) Target Study design Intervention Effects of berberine Conclusion Reference
Zhang B (2018) T2DM In vitro: primary 
hepatocytes; in vivo: mice
In vitro: berberine 5 
and 10 µmol/L; in 
vivo: berberine 150 
mg/kg for 7 d (p.o.)
In vitro: reduced mitochondrial membrane potential; reduced SIRT3 expression; 
inhibited oxygen consumption rate (complex I activity) in WT cells, but not in 
Sirt3-/- cells; enhanced glucose uptake and glycolysis and inhibited glucagon-
induced gluconeogenesis; increased AMP and decreased cAMP as effectively 
as nicotinamide (SIRT3 inhibitor) in WT cells, but not in Sirt3-/-; suppressed 
glucagon-induced PKA phosphorylation. In vivo: enhanced glucose and 
pyruvate tolerance; inhibited glucagon-induced glucose generation.
Berberine promotes glucose uptake and inhibits 
gluconeogenesis via SIRT3 inhibition.
[109]
Liu D (2018) Fatty liver 
disease
In vivo: HFD-induced 
obesity model in rats
Berberine 200 
mg/(kgd) for 8 
weeks (p.o.)
Reduced FBG, FINS, TAG and LDL-C; reduced lobular inflammation; 
inhibited HFD-induced liver damage, reduced TLR4 and TNF-α, and induced 
insulin IR (IRc), and IR substrate (IRS)-1 in the liver.
Berberine may reduce insulin resistance via inhibiting 








In vivo: STZ-induced 
diabetic model in rats
Berberine 50 
mg/(kgd) for 45 d 
(p.o.)
Restored liver glycogen; ameliorated upregulation of hepatic markers; 
suppressed abnormality in carbohydrate metabolism; reduced lipid peroxidation 
and restored antioxidant levels; suppressed inflammatory response in the liver 
and reduced liver damage; restored Bcl2 and suppressed Bax.
Berberine protects the liver from hyperglycemia-induced 
imbalance in antioxidants and carbohydrate metabolism, 
inflammation and apoptosis.
[107]
Sun Y (2018) Hepatic 
steatosis
In vivo: HFHS diet-
induced hepatic steatosis in 
mice
Berberine 5 
mg/(kgd) (i.p.) for 
5 weeks
Reduced liver triglyceride; induced autophagy in the liver; induced FGF21; 
increased oxygen consumption, energy expenditure and the expression of 
brown-like genes (UCP1, DIO2, PRDM16) in the liver.
Berberine regulates lipid utilization and energy 
metabolism in the liver via autophagy, FGF21 signaling 
activation, and brown-like gene induction.
[106]
Wei S (2016) Hyperglycemia 
and 
hyperlipidemia 
In vivo: STZ and HFD-
induced diabetic model in 
mice; in vitro: HepG2 cells 
exposed to palmitate
In vivo: berberine 
160 mg/(kgd) for 4 
weeks (p.o.); in 
vitro: berberine 10 
µmol/L
In vivo: lowered FBG and restored FINS; improved glucose tolerance; reduced 
TC and TAG; increased HDL-C; reduced alanine aminotransferase and 
aspartate aminotransferase levels; suppressed liver pathology; suppressed 
gluconeogenesis and lipogenesis. In vitro effects on HepG2: inhibited 
palmitate-induced HNF-4α expression; inhibited palmitate-induced 
gluconeogenesis and lipogenesis.
Berberine attenuates hepatic gluconeogenesis and 
lipogenesis in diabetes via HNF-4α signaling inhibition.
[105]
Li F (2016) Insulin 
resistance of 
hepatocytes
In vitro: insulin resistance 
model in HepG2 cells
Berberine 10 
µmol/L
Enhanced glucose up-take; inhibited AChE and restored α7nAChR expression; 
inhibited NF-B activation and reduced IL-6 levels.
Berberine enhances glucose uptake and relieves insulin 
resistance and inflammation in the liver, possibly via 
inhibition of AChE.
[104]
Zhang Y (2015) NAFLD In vivo: HFD-induced 
NAFLD model in rats
Berberine 200 
mg/(kgd) for 16 
weeks (p.o.)
Suppressed HFD-induced body weight gain, as well as visceral fat and liver 
weight increase; restored L-type pyruvate kinase (L-PK) mRNA expression and 
activity in the liver; suppressed HFD-induced hypermethylation of L-PK 
promoter, and restored histone acetylation around L-PK.
Berberine may alleviate NAFLD by improving glycolysis 
in the liver through restoration of L-PK expression.
[103]
Jiang SJ (2015) Liver 
dysfunction in 
diabetes
In vivo: STZ and HFD-
induced diabetic model in 
rats
Berberine 156 
mg/(kgd) for 12 
weeks (p.o.)
Improved glucose tolerance, decreased plasma hyperlipidemia, and reduced 
fasting plasma insulin and insulin resistance; restored AMPK and phospho-
AMPK levels, and its upstream LKB1 in the liver; upregulated cytoplasmic 
phospho-TORC2 (inhibition of TORC2 nuclear localization) in the liver; 
downregulated the expression of gluconeogenic enzymes in the liver.








In vivo: STZ-induced 
diabetic model in mice
Berberine 100 
mg/(kgd) for 2 
weeks (p.o.)
Reduced FBG; restored hepatic CuZn-SOD; reduced oxidative stress (MDA 
levels) in the liver; improved catalase activity in the liver.
Berberine may alleviate oxidative stress in the liver. [43]
Teodoro JS (2013) Hepatic 
dysfunction in 
obesity
In vivo: HFD-induced 
obesity model in rats
Berberine 100 
mg/(kgd) for 4 
weeks (p.o.)
Reduced HFD-induced weight gain and HFD-induced insulin, and enhanced 
oral glucose tolerance; increased unsaturated fatty acids in the liver; protected 
hepatic mitochondria from HFD-induced dysfunctions (membrane potential, 
oxidative phosphorylation and ATP generation).
Berberine protects liver mitochondria from HFD-induced 
dysfunctions.
[101]
Lao-ong T (2012) Oxidative stress 
in the liver
In vivo: STZ-induced 
diabetic model in mice
Berberine 200 
mg/(kgd) for 2 
weeks (p.o.)
Inhibited STZ-induced downregulation of CuZn-SOD and Mn-SOD in the liver; 
suppressed STZ-induced upregulation of GPx; restored GSH and GSSG 
contents to normal levels.
Berberine alleviates oxidative stress in the liver. [99]
Xie X (2011) Liver glycogen 
reduction in 
diabetes
In vivo: alloxan-induced 
diabetic model in mice
Berberine 300 
mg/(kgd) for 12 
weeks (p.o.)
Reduced FBG; restored liver glycogen; restored Akt phosphorylation and 
GSK3 phosphorylation; restored glucokinase activity and IRS phosphorylation 
in the liver.
Berberine ameliorates hyperglycemia and restores liver 
glycogen via restoration of glucokinase activity, Akt 
signaling and GSK3 inactivation. 
[98]
Zhou JY (2011) Liver 
dysfunction
In vivo: STZ-induced 
diabetic model in rats
(hyperlipidemia induced 
by HFD)
Berberine 150 and 
300 mg/(kgd) for 
16 weeks (p.o.)
Restored catalase, SOD, GPx and GSH in the serum and the liver; reduced 
MDA in the serum and the liver; restored cyclin-dependent kinase 9 and cyclin 
T1 expression in the liver.
Berberine protects the liver by inducing antioxidants via 
upregulation of P-TEFb.
[97]
Liu X (2010) Hepatic insulin In vivo: HFD and STZ- Berberine 150 Improved oral glucose tolerance; alleviated liver weight increase; reduced blood Berberine protects the liver via modulating metabolic [95]
resistance induced T2DM model in 
hamster
mg/(kgd) for 9 
weeks (p.o.)
glucose, serum insulin, TC, TAG, FFA, and LDL-C; reduced the expression of 
SREBPs and target genes and restored the expression of LXR and PPAR, as 
well as their target genes in the liver.
regulators such as LXR, SREBPs, and PPAR in the 
liver, thereby improving hepatic glucose utilization and 
lipid metabolism.
AChE: acetylcholinesterase; AChR: acetylcholinesterase receptor; AMPK: 5'-adenosine monophosphate-activated protein kinase; FBG: fasting blood glucose; FFA: free fatty acid; FGF21: fibroblast growth factor 21; FINS: fasting 
insulin; GPx: glutathione peroxidase; GSH: reduced glutathione; GSK3: glycogen synthase kinase 3 ; GSSG: oxidized glutathione; HDL-C: high-density lipoprotein cholesterol; HFD: high-fat diet; HFHS: high fat and high 
sucrose; HNF-4: hepatocyte nuclear factor 4; IL: interleukin; i.p.: intraperitoneal injection; IR: insulin receptor; IRS: insulin receptor substrate; LDL-C: low-density lipoprotein cholesterol; LKB1: liver kinase B1; LPS: 
lipopolysaccharide; LXR: liver X receptor; MDA: malonaldehyde; NAFLD: non-alcoholic fatty liver disease; NF-κB: nuclear factor κB; P-TEFb: positive transcription elongation factor b; PKA: protein kinase A; p.o.: per os; PPAR: 
peroxisome proliferator-activated receptor; SIRT: sirtuin; SOD: superoxide dismutase; SREBP: sterol regulatory element-binding protein; STZ: streptozotocin; T2DM: type 2 diabetes mellitus; TAG: triacylglycerol; TC: total 
cholesterol; TLR-4: toll-like receptor 4; TNF-α: tumor necrosis factor-α; TORC2: target of rapamycin complex-2; WT: wildtype.
Table 6. Research articles studying the use of berberine to treat kidney dysfunction of diabetes.
First author 
(Year)
Target Study design Intervention Effects of berberine Conclusion Reference




In vivo: STZ-induced 
diabetic nephropathy 
model in rats; in vitro: 
HG-induced diabetic 
nephropathy model in 
podocytes
In vivo: berberine 100, or 200 
mg/(kgd) (p.o.); in vitro: 
Berberine 30 or 90 µmol/L
In vivo, berberine’s effects in DN model: ameliorated renal injury in the DN model; ameliorated 
inflammation in the blood and renal cortex; inhibited TLR4/NF-κB pathway. In vitro: 
berberine’s effects in HG-induced DN model: suppressed podocyte apoptosis; suppressed 
inflammation in podocytes; reduced HG-induced upregulation of TLR4 and inhibited NF-B 
signaling.
Berberine ameliorates DN, 
relieving STZ-induced renal 
injury, inflammatory response and 
HG-induced podocyte apoptosis, 









In vitro: HG-induced 
injury model in rat 
GMCs and podocytes
Berberine treatment (50 and 100 
µmol/L) of GMCs
Suppressed HG-induced proliferation of GMCs; suppressed GMC-derived exosome-induced 
injury in podocytes; suppressed GMC-derived exosome-induced PI3K activation, Akt 
phosphorylation, p65 phosphorylation, and TGFβR induction (TGF-β1/PI3K-Akt pathway).
Berberine protects the function of 
podocytes via inhibition of TGF-β 
signaling from GMCs.
[94]




In vivo: STZ-induced 
diabetic nephropathy 
model in rats
Berberine 400 mg/(kgd) for 12 
weeks.
Alleviated glomerular hypertrophy and mesangial matrix expansion; suppressed TGF-β, α-SMA, 
vimentin and NF-B in the kidneys.
Berberine inhibits renal fibrosis 
associated with diabetes via 
suppression of TGF-β and NF-B 
signaling.
[93]




In vitro: HG-induced 
podocyte (MPC5) injury 
model
In vitro: berberine 2.5 and 5 
µmol/L
Enhanced podocyte survival under HG; protected podocytes from HG-induced apoptosis via 
autophagy induction; induced AMPK activation; enhanced autophagy in podocytes under HG 
via AMPK.
Berberine enhances autophagy and 
protects podocytes from HG-





Renal fibrosis In vivo: renal fibrosis in 
STZ-induced diabetic 
model in mice; in vitro: 
HG-induced EMT
In vivo: berberine 200 mg/(kgd) 
for 12 weeks. (p.o.); in vitro: 
normal rat kidney tubular 
epithelial cells (NRK 52E) 
exposed to HG
In vivo: reduced FBG, kidney weight/body weight ratio, SCr, BUN and albuminuria; suppressed 
fibrosis by inhibiting EMT (α-SMA and collagen-1 expression); enhanced Nrf2/HO-1 signaling. 
In vitro: suppressed HG-induced EMT; enhanced HO-1 and NQO1 expression via Nrf2 
signaling; suppressed HG-induced TGF-β/Smad signaling.
Berberine inhibits diabetic kidney 
fibrosis via inhibition of EMT 
through enhancement of Nrf2 
signaling and inhibition of TGF-
β/Smad signaling.
[91]
Ni WJ (2016) Diabetic 
nephropathy
In vivo: STZ and HF/HG 
diet-induced diabetic 
model in rats; in vitro: 
GMCs exposed to HG
Berberine 100 mg/(kgd) for 8 
weeks (p.o.)
In vivo, berberine’s effects in diabetic model: reduced blood glucose, kidney/body weight ratio, 
urine total protein and creatinine ratio (UTP/C), BUN, SCr; ameliorated renal pathology; 
reduced PGE2 and EP1 expression. In vitro, berberine’s effects in HG-exposed GMCs: reduced 
PGE2-EP1 signaling; suppressed GMCs proliferation.
Berberine is renoprotective, 
possibly via inhibition of PGE2-








In vivo: STZ and HF/HG 
diet-induced diabetic 
nephropathy model in 
rats
Berberine 100 and 200 mg/(kgd) 
for 8 weeks (p.o.)
Berberine ameliorated renal pathology; berberine restored β-arrestin 1 and β-arrestin 2 and 
suppressed ICAM-1 and VCAM-1 in diabetic kidneys.
Berberine inhibits ECM 
accumulation in the kidneys, 
possibly via restoration of β-
arrestin levels.
[88]




In vivo: STZ-induced 
diabetic nephropathy 
model in rats
Berberine 100 and 200 mg/(kgd) 
for 8 weeks (p.o.)
Berberine’s effects in diabetic nephropathy: lowered FBG, BUN and SCr, and suppressed 
albuminuria and kidney weight increase; suppressed type IV collagen and FN expression in the 
kidney; restored the expression of MMP-2 and attenuated the induction of MMP-9, TIMP-2 and 
TMIP-9 in the kidney; suppressed TGF-β expression in the kidney.
Berberine protects the kidney, 








In vivo: STZ and HFD-
induced diabetic model 
in rats
Berberine 25 mg/(kgd) for 20 
weeks (p.o.)
Reduced blood glucose and lipids (TC, TAG and LDL-C) and albuminuria; attenuated kidney 
injury; inactivated NF-B signaling and inhibited renal inflammation; inactivated TGF-β/Smad3 
signaling and suppressed renal fibrosis.
Berberine inhibits kidney 
dysfunction via suppression of 
renal inflammation and fibrosis via 
inactivation of NF-B and TGF-β 
signaling in the kidneys.
[86]
Yang Y (2014) Diabetic 
nephropathy
In vivo: HG/HF diet and 
STZ-induced diabetic 
model in rats
Berberine 100 and 200 mg/(kgd) 
for 8 weeks (p.o.)
Suppressed increase in kidney weight/body weight ratio; suppressed increase in albuminuria, 
BUN and SCr; restored production of EP4 and G protein Gs α subunit (Gαs) and cAMP levels in 
renal cortex; ameliorated renal injury and delayed glomerular fibrosis.
Berberine restores renal functional 








In vitro: hypertrophy and 
HF-induced proliferation 
and hypertrophy of 
mesangial cells from rat 
kidneys
Berberine 30 µmol/L Attenuated HG-induced mesangial cell proliferation and hypertrophy; inhibited HF-induced cell 
cycle progression (S phase); restored HG-induced suppression of cyclin-dependent kinase 
inhibitors p21 and p27; suppressed HG-induced TGF-β1 and FN expression; suppressed HG-
induced NF-B and AP-1 activation and c-jun phosphorylation.
Berberine attenuates HG-induced 
TGF-β expression, cell cycle 
progression, mesangial cell 
proliferation and hypertrophy 
possibly via inhibition of HG-







In vivo: HFD and STZ-
induced diabetic model 
in rats
Berberine 100 and 200 mg/(kgd) 
for 8 weeks (p.o.)
Attenuated renal damage, hyperglycemia and hyperlipidemia; reduced IL-6 and PGE2 levels in 
renal cortex; restored the expression levels of prostaglandin receptors (EP1, EP3, and EP4) in 
renal cortex.
Berberine alleviates kidney 
dysfunction via modulation of 
prostaglandin signaling.
[83]
Xie X (2013) Renal 
inflammation 
and fibrosis
In vitro: GMCs isolated 
from rats, exposed to 
HG; in vivo: STZ-
induced diabetes in rats
In vitro: berberine 30 and 90 
µmol/L; in vivo: berberine 200 
mg/(kgd) for 12 weeks
In vitro: inhibited HG-induced NF-B and Ras homolog gene family, member A (RhoA)/Rho-
associated protein kinase (ROCK) activation; reduced induction of FN, ICAM-1 and TGF-. In 
vivo: reduced STZ-induced glomerular injury; reduced FN accumulation in the kidneys; reduced 
NF-B and RhoA/ROCK activation; inhibited ICAM-1 and TGF- induction.
Berberine ameliorates diabetes-
induced renal inflammation and 
fibronectin accumulation, by 









In vivo: HFD and STZ-
induced diabetic model 
in rats
Berberine 100 and 200 mg/(kgd) 
for 8 weeks (p.o.)
Reduced FBG, triglyceride, TC and LDL-C levels in diabetic rats; ameliorated kidney 
hypertrophy and inflammation; reduced type IV collagen and TGF- expression in the kidneys; 
improved renal functions (reduced BUN, SCr, urine microalbumin/creatinine, and urine 
protein/creatinine); restored G protein-coupled receptor kinase (GRK) expression patterns and 
cAMP levels in renal cortex.
Berberine exerts renoprotection in 
diabetes possibly via modulating 
G protein-adenylate cyclase-cAMP 
signaling pathway.
[82]
Lan T (2012) Mesangial 
hypertrophy
In vitro: GMCs isolated 
from rats, exposed to 
HG
Berberine 30 and 90 µmol/L Inhibited HG-induced mesangial hypertrophy and -SMA formation; suppressed HG-induced 
TGF- and FN expression; inhibited HG-induced SphK1 activation; suppressed HG-induced 
AP-1 activation.
Berberine protects against 
mesangial hypertrophy by 





Renal fibrosis In vitro: GMCs isolated 
from rats, exposed to 
HG; in vivo: STZ-
induced diabetes in rats
In vitro: berberine 10 30, and 90 
µmol/L; in vivo: berberine 200 
mg/(kgd) for 12 weeks (p.o.)
In vitro: reduced HG-induced SphK1-sphingosine 1-phosphate (S1P2) receptor expression in 
GMCs; suppressed S1P2 receptor-mediated FN expression under HG; inhibited HG-induced 
NF-B activation.In vivo: reduced diabetes-induced S1P2 receptor expression in the kidneys; 
reduced FN expression in the kidneys.
Berberine suppresses diabetic 
renal fibrosis via inhibiting NF-B 
activation and downregulating 
S1P2 receptor expression.
[81]
Wu D (2012) Diabetic 
nephropathy
HFD and STZ-induced 
diabetic model in rats
In vivo: berberine 100 and 200 
mg/(kgd) for 8 weeks
Alleviated weight loss and reduced blood glucose, HbA1c, urine volume and urine protein; 
restored kidney weight and Ccr and reduced SCr and BUN; reduced MDA and increased SOD in 
the kidneys; restored nephrin and podocin expression.
Berberine exerts renoprotective 
effects via inhibiting oxidative 
stress and restoring podocytes 
survival.
[79]
Lan T (2010) Renal 
hypertrophy
Alloxan-induced 
diabetic model in mice
In vivo: berberine 300 mg/(kgd) 
for 12 weeks (p.o.)
Reduced FBG, kidney/body weight ratio, BUN, SCr and 24 h albuminuria; prevented renal 
hypertrophy, TGF- upregulation, and FN and collagen IV accumulation; downregulated SphK 
and S1P expression.
Berberine prevents renal 
hypertrophy via inhibiting SphK-
S1P signaling.
[77]
Liu W (2010) Renal fibrosis Alloxan-induced 
diabetic model in mice
Berberine 300 mg/(kgd) for 12 
weeks (p.o.)
Improved blood glucose, BUN and SCr levels; reduced NF-B nuclear localization and 
expression in the kidney; restored IB- expression in the kidney; suppressed ICAM-1, TGF-1 
and FN induction in the kidney
Berberine prevents renal fibrosis 
via suppressing matrix 
accumulation by inhibiting NF-B 
activation. 
[76]
AMPK: 5'-adenosine monophosphate-activated protein kinase; AP-1: activator protein 1; BUN: blood urea nitrogen; cAMP: cyclic adenosine monophosphate; Ccr: creatinine clearance; DN: diabetic nephropathy; ECM: extracellular 
matrix; EMT: epithelial-mesenchymal transition; EP: prostaglandin E2 receptor; FBG: fasting blood glucose; FN: fibronectin; GMC: glomerular mesangial cell; HbA1c: glycosylated hemoglobin A1c; HF: high fat; HFD: high-fat 
diet; HG: high glucose; HO-1: heme oxygenase-1; ICAM-1: intercellular adhesion molecule-1; LDL-C: low-density lipoprotein cholesterol; MDA: malonaldehyde; MMP: matrix metallopeptidase; NF-κB: nuclear factor κB; NQO-1: 
NADPH quinone oxidoreductase-1; PGE2: prostaglandin E2; PI3K: phosphoinositide 3-kinase; p.o.: per os; S1P: sphingosine 1-phosphate; SCr: serum creatinine; SMA: myofibroblast differentiation marker; SOD: superoxide 
dismutase; SphK: sphingosine kinase; STZ: streptozotocin; TAG: triacylglycerol; TC: total cholesterol; TGF-β: transforming growth factor-β; TGF-βR: transforming growth factor-β receptor; TIMP: tissue inhibitor of the matrix 
metalloproteinase; TLR-4: toll-like receptor 4; VCAM-1: vascular cell adhesion molecule-1.










In vivo: atherosclerosis model 
mice (ApoE-/- mice fed with HFD)
Berberine 50 mg/kg for 12 
weeks (p.o.); cohousing with 
berberine-treated mice
Berberine and cohousing: increased Verrucomicrobia and inhibited HFD-induced 
suppression of Firmicutes; suppressed trimethylamine-N-oxide and flavin-containing 
monooxygenase 3 induction by HFD; reduced HFD-induced inflammatory response
(berberine attenuated HFD-induced atherosclerosis).
The anti-atherosclerotic effect of 








In vivo: HFD-induced obesity 
model in mice; in vitro: palmitate-
induced mitochondrial stress 
model in intestinal epithelial cells 
(NCl-H716)
Berberine 100 mg/(kgd) 
dietary supplementation for 8 
weeks
In vivo: reduced body weight, tissue weight of perirenal fat and epididymal fat pads, 
TC, TAG and LDL-C, increased HDL-C, improved insulin sensitivity and glucose 
tolerance and reduced gluconeogenesis; enhanced GLP-1 and G protein-coupled 
receptor 43 expression; restored mucosal and mitochondrial structure in colon; restored 
mitochondrial function; suppressed HFD-induced activation of complex I, and 
inactivation of complexes II and IV; partly restored SCFAs reduced by HFD and had 
significant impact on gut microflora (reduced Firmicutes, recovered Bacteroidetes, 
increased Clostridiales, Oscillospira, Parabacteroides and Mogibacteriaceae). In 
vitro: inhibited palmitate-induced ATP elevation, MMP disruption, respiration 
inhibition and apoptosis.
Berberine prevents metabolic 
dysfunctions possibly via restoring gut 
microbiota, GLP-1 expression, and 
SCFAs, as well as protecting intestinal 










model in ApoE-/- mice
Berberine in drinking water 
(0.5 g/L) for 14 weeks
Prevented inflammation in the intestine; promoted intestinal epithelial barrier integrity; 
increased Verrucomicrobia, particularly Akkermansia and Bacterooides; increased the 
number of intestinal goblet cells and restored the thickness of mucus layer.
Berberine modulates gut microbiota, 
specifically increases the abundance of 






associated with FLD 
In vivo: HFD-induced obesity 
model in rats
Berberine 200 mg/(kgd) for 
8 weeks (p.o.)
Reduced Escherichia coli and increased Lactobacillus in the gut microbiota; reduced 
plasma endotoxin.
Berberine modulates the gut 








In vivo: HFD-induced gut 
microbial dysbiosis model in rats
Berberine 100 or 200 
mg/(kgd) for 18 weeks (p.o.)
Reduced body weight and obesity index; reverted HFD-induced population shift in gut 
microbiota; increased SCFA-producing bacteria, including Allobaculum, Bacteriodes, 
Blautia, Butyricoccus and Phascolarctobacterium.





Intestinal glucose and 
lipid metabolism
In vivo: STZ and HFD-induced 
diabetic model in rats
Berberine 120 and 240 
mg/(kgd) for 6 weeks (p.o.)
Reduced FBG and FINS and restored oral glucose tolerance; restored postprandial 
GLP-1 levels; upregulated GLP-1 receptor and downregulated GnRH and GnRH 
receptor expression in the ileum.
Berberine improves blood glucose 
levels, possibly via GnRH-GLP-1 






In vivo: HFD and STZ-induced 
diabetes in rats
Berberine 100 mg/kg for 2 
weeks (p.o.)
Improved insulin resistance; restored intestinal mucosa structure and reduced plasma 
LPS; restored glutamine-induced GLP-2 secretion from ileum.
Berberine treatment augments GLP2 







with obesity and 
metabolic disorders
In vivo: HFD-induced obesity and 
insulin resistance in rats
Berberine 100 mg/(kgd) for 
18 weeks (p.o.)
Prevented obesity and improved insulin sensitivity; prevented systemic inflammation; 
reduced the bacterial diversity of the gut microbiota; reduced total bacterial population 
under HFD; enriched Allobaculum and Blautia (SCFA producers); increased fecal 
SCFA levels.
Berberine prevents HFD-induced 
obesity and insulin resistance at least 







In vivo: postmaltose (in rats and 
dogs) and postglucose blood 
glucose (in rats); insulin 
sensitivity test in rats. In vitro: 
maltose digestion and glucose 
transport by enterocytes (Caco-2); 
-glycosidase inhibition assay
In vivo: rats, berberine 500 
mg/kg (p.o.); dogs, 80 mg/kg, 
1 h before tests.In vitro: 
Berberine 250 mg/L
In vivo: delayed postmaltose blood glucose in rats and dogs; did not affect postglucose 
blood glucose in rats; had no effect on insulin levels. In vitro: inhibited maltose 
digestion by Caco-2 cells; inhibited -glycosidase activity.
Berberine acutely inhibits digestion of 






In vivo: STZ-induced diabetic 
model in rats; in vitro: intestinal 
epithelial cells (Caco-2)
In vivo: berberine 100 and 
200 mg/(kgd) for 5 weeks 
(p.o.); in vitro: berberine 10 
and 50 µmol/L
In vivo: reduced food intake and blood glucose and restored serum insulin level; 
decreased sucrase and maltase activity and SI complex expression in the small 
intestine; reduced blood glucose after oral sucrose or maltose administration. In vitro: 
inhibited sucrase and maltase activity, which was suppressed by H-89 (PKA inhibitor); 
inhibited SI complex mRNA expression.
Berberine suppresses disaccharidase 
activity and SI complex mRNA 
expression, which has beneficial 
metabolic effects. The effect involves 
PKA-dependent pathway.
[68]
ATP: adenosine triphosphate; FBG: fasting blood glucose; FINS: fasting insulin; FLD: fatty liver disease; GLP: glucagon-like peptide; GnRH: gonadotropin-releasing hormone; HDL-C: high-density lipoprotein cholesterol; HFD: 
high-fat diet; LDL-C: low-density lipoprotein cholesterol; LPS: lipopolysaccharide; MetS: metabolic syndrome; MMP: matrix metallopeptidase; PKA: protein kinase A; p.o.: per os; SCFA: short-chain fatty acid; SI complex: 
sucrase-isomaltase complex; STZ: streptozotocin; T2DM: type 2 diabetes mellitus; TAG: triacylglycerol; TC: total cholesterol.









In vitro: HG-induced primary 
Müller cell apoptosis 
(diabetic retinopathy) model
Berberine 10 and 
20 µmol/L
Improved viability of Müller cells under HG; restored phospho-AMPK levels 
and suppressed phospho-mTOR levels against HG; induced autophagy 
(Beclin1 and LC3I/II expression); inhibited HG-induced apoptosis (Bcl2 and 
Bax).
Berberine may protect Müller cells from HG-induced 
apoptosis via activation of AMPK signaling, suppression 






In vitro: human Müller cell 





Berberine pretreatment attenuated negative effects of HOG-LDL on Müller 
cells: improved cell viability; enhanced Nrf2 and GPx-1; suppressed Nox4 and 
ROS generation; suppressed autophagy and apoptosis; inhibited angiogenesis, 
glial activation and inflammation; activated AMPK signaling.
Berberine inhibits oxidative stress and HOG-LDL-







In vitro: leukocyte-mediated 
death of retinal endothelial 
cells (human retinal 
endothelial cells cocultured 
with leukocyte isolated from 
diabetic patients)
 In vitro: 
berberine 5, 25 
and 50 µmol/L; 
ex vivo: berberine 
0.5 g, twice/day 
for 1 month
Berberine inhibited leukocyte-mediated retinal endothelial cell apoptosis; 
inhibited leukocyte adhesion to retinal endothelial cells; inhibited HG-induced 
NF-B activation in retinal endothelial cells; inhibited HG-induced oxidative 
stress via SOD, catalase and GPx induction. Leukocytes from diabetic patients 
after berberine treatment were less damaging to retinal endothelial cells.
Berberine may prevent diabetic retinopathy via 
protection of retinal endothelial cells and inhibiting HG-
induced leukocyte activation.
[64]
AMPK: 5'-adenosine monophosphate-activated protein kinase; GPx: glutathione peroxidase; HG: high glucose; HOG: highly oxidized; glycated; LDL: low-density lipoprotein; mTOR: mammalian target of rapamycin; NF-κB: 
nuclear factor κB; ROS: reactive oxygen species; SOD: superoxide dismutase.




Target Study design Intervention Effects of berberine Conclusion Reference
Yerra VG 
(2018)




In vivo: STZ-induced 
diabetic model in rats; 
in vitro: HG-exposed 
in N2a cells
In vivo: berberine 50 and 
100 mg/(kgd) for 2 
weeks (p.o.); in vitro: 
berberine 5 and 10 
µmol/L
In vivo: reduced plasma glucose and MDA, and increased GSH; ameliorated motor and 
sensory dysfunctions; reduced DNA fragmentation in sciatic nerve; restored phospho-
AMPK and ATP levels; reduced IL-6 and TNF-α in sciatic nerves; restored the levels 
of antioxidative stress proteins and mitochondrial biogenesis-related proteins. In vitro, 
berberine’s effects in HG-exposed neurons: induced mitochondrial biogenesis and 
restored membrane potential; restored phospho-AMPK and Nrf2 levels.
Berberine activates AMPK. Berberine 
alleviates neurotoxicity in diabetes, 
possibly via protecting mitochondria and 





Diabetic neuropathy In vivo: STZ and high 
sugar/high fat-induced 
diabetic model in rats
Berberine 100 mg/(kgd) 
for 24 weeks (p.o.)
Reduced FBG, HbA1c, TAG and TC; restored somatosensory transmission; protected 
hippocampal CA1 neurons; restored neuritin expression; downregulated 
phosphorylation of p38 and JNK, but not ERK in the hippocampus.
Berberine has a beneficial effect against 
diabetic neuropathy possibly via neuritin 





Diabetic neuropathy In vivo: STZ-induced 
diabetes in rats
Berberine 10 and 20 
mg/kg for 1 or 2 weeks 
(i.p.)
Single and two-week administration of berberine exhibited anti-allodynic effects. Berberine could be anti-allodynic 
possibly via anti-inflammatory or 
antidepressant capacity.
[61]
AMPK: 5'-adenosine monophosphate-activated protein kinase; ATP: adenosine triphosphate; CA: calyculin A; ERK: extracellular signal-regulated kinase; FBG: fasting blood glucose; GSH: reduced glutathione; HbA1c: 
glycosylated hemoglobin A1c; HG: high glucose; IL: interleukin; i.p.: intraperitoneal injection; JNK: c-Jun N-terminal kinase; MDA: malonaldehyde; p.o.: per os; STZ: streptozotocin; TAG: triacylglycerol; TC: total cholesterol; 
TNF: tumor necrosis factor.
Table 10. Research articles studying the use of berberine to treat other associated disorders of diabetes.
First author 
(Year)
Target Study design Intervention Effects of berberine Conclusion Reference
Memon MA 
(2018)
T2DM Clinical: case-control with 
population as newly diagnosed 
type 2 diabetic patients (n = 200)
Group 1: metformin 200 mg (three 
times per day) for 3 months; Group 
2: berberine 500 mg (three times per 
day) for 3 months 
Berberine reduced blood glucose, cholesterol, TAG, LDL-C, 
HbA1c, insulin resistance and methylglyoxal.
Berberine is effective in treating T2DM. 
Berberine is more effective than metformin.
[60]




In vivo: T2DM model using 
Zucker diabetic fatty rats (fa/fa) 
fed with HFD
Berberine 300mg/(kgd) for 12 
weeks (p.o.)
In vivo: reduced serum HbA1C, insulin, TC and TAG; restored the 
glyoxylate and dicarboxylate metabolism, pentose and glucuronate 
interconversions and sphingolipid metabolism.
Berberine is antidiabetic via restoration of 
glycometabolism and lipometabolism.
[58]
Liu C (2015) Hyperglycemia and 
hyperlipidemia
STZ and HG/HFD-induced 
diabetic model in hamsters
Berberine 100 mg/(kgd) for 6 
weeks (p.o.)
Reduced body and liver weight gain, FBG, insulin, and serum lipid 
(TC, TAG, and LDL-C) levels; reduced oxidative stress (reduced 
plasma MDA and increased plasma SOD); reduced apolipoprotein B 
and increased apolipoprotein A1 levels; induced GLUT4 in the 
skeletal muscle and LDL receptor in the liver.
Berberine is effective against hyperglycemia 
and hyperlipidemia and reduces oxidative 
stress, possibly via enhancing glucose 
consumption in the muscle and lipid 
metabolism in the liver.
[59]
Xu M (2014) Hyperglycemia In vitro: hepatocytes (HepG2) and 
myoblasts (C2C12)
Berberine 20 µmol/L Inhibited mitochondrial complex I and reduced ATP synthesis in 
myoblasts; increased glucose consumption and lactate release in 
both hepatocytes and myoblasts; enhanced AMPK and acetyl 
coenzyme A synthetase phosphorylation, and AMPK inhibition.
Berberine enhances glucose consumption 
possibly via shifting cellular metabolism from 
mitochondrial oxidative phosphorylation to 




Glucose uptake by 
skeletal muscles
In vitro: myotubes (differentiated 
C2C12 cells)
Berberine 6.25 and 12.5µg/mL for 
24 h
Berberine enhanced glucose uptake. Berberine may help alleviate hyperglycemia 
by promoting glucose uptake by skeletal 
muscles.
[143]
Chen Y (2011) Glucose 
homeostasis
In vivo: STZ-induced diabetic 
model in rats; in vitro: DPP-4 and 
PTP1B assay
Berberine 100 mg/(kgd) for 7 
weeks (p.o.)
Reduced FBG; improved oral glucose tolerance; reduced plasma 
lipids (TC, HDL-C, LDL-C, and TAG) and FFA; inhibited DPP-4 
and PTP1B.
Berberine improves glucose homeostasis via 
inhibition of DPP-4 and PTP1B, thereby 





Hyperglycemia In vivo: spontaneous type 1 
diabetes model in mice
Berberine 50, 150, 500 mg/(kgd) 
for 14 weeks (p.o.)
Serum berberine concentration was negatively associated with serum 
glucose levels.
Berberine improves hyperglycemia in type 1 
diabetes.
[122]
Cok A (2011) Cellular glucose 
uptake
In vitro: fibroblast (L929) Berberine 10–100 µmol/L Enhanced glucose uptake Berberine activates cellular glucose uptake via 




Hyperglycemia In vivo: HFD and STZ-induced 
diabetic model in rats
Berberine 50, 100, and 150 
mg/(kgd) for 6 weeks (p.o.)
Reduced blood glucose and improved OGTT; reduced food intake; 
did not change plasma insulin levels; did not change SOD, MDA or 
GSH in the liver.
Berberine is hypoglycemic via unknown 
mechanism.
[78]
Chen C (2010) Glucose uptake In vitro: adipocytes (3T3-L1) and 
myocytes (L6); in vivo: HFD-
induced obesity and leptin 
receptor deficient (db/db) mice
In vitro: berberine 1.25–20 µmol/L; 
in vivo: berberine 100 mg/(kgd) for 
2 weeks (p.o.)
In vitro: promoted glucose uptake by 3T3-L1 and L6 cells; inhibited 
PTP1B and increased IR phosphorylation; increased insulin 
signaling (phospho-IRS, phosphor-Akt). In vivo: reduced blood 
glucose; did not increase plasma insulin level and insulin synthesis 
in pancreas; activated insulin signaling.
Berberine mimics insulin action via inhibition 
of PTP1B activity.
[100]
Ma X (2010) Glucose transport in 
skeletal muscles
In vitro: skeletal muscles isolated 
from rats
Berberine 0.3 mmol/L Induced AMPK phosphorylation and increased AMPK activity; 
stimulated glucose transport in the absence of insulin; increased 
AS160 phosphorylation (downstream of AMPK); decreased PCr 
content.
Berberine reduces the intracellular energy 
status and acutely stimulates AMPK and 
insulin-independent glucose transport in 
skeletal muscle.
[89]




Clinical: T2DM patients (n = 60); 
metabolomics
Berberine 1.0 g/d for 3 months Reduced fasting and postload plasma glucose, HbA1c, TAG, TC and 
LDL-C; reduced FFAs including C16:0 and C18:0.
Berberine is effective in treating T2DM 




Hyperglycemia Clinical: T2DM patients; in vitro: 
human cell lines (CEM, HCT-
116, SW1990, HT1080, 293T and 
human liver cells)
Clinical: berberine 1.0 g/d for 2 
months; in vitro: berberine 2.5–15 
µmol/L
Clinical: increased IR expression; lowered blood glucose and 
HbA1c. In vitro: upregulated IR; sensitized IR and Akt 
phosphorylation to low-dose insulin.
Berberine lowers blood glucose in T2DM 
through upregulation of IR.
[22]
AMPK: 5'-adenosine monophosphate-activated protein kinase; ATP: adenosine triphosphate; DPP-4: dipeptidyl peptidase-4; ERK: extracellular signal-regulated kinase; FBG: fasting blood glucose; FFA: free fatty acid; GLP: 
glucagon-like peptide; GLUT: glucose transporter; GSH: reduced glutathione; HbA1c: glycosylated hemoglobin A1c; HFD: high-fat diet; HG: high glucose; IR: insulin receptor; IRS: insulin receptor substrate; LDL: low-density 
lipoprotein; LDL-C: low-density lipoprotein cholesterol; MAP: mitogen-activated protein; MDA: malonaldehyde; OGTT: oral glucose tolerance test; PCr: phosphocreatine; PTP1B: protein tyrosine phosphatase 1B; SOD: superoxide 
dismutase; STZ: streptozotocin; T2DM: type 2 diabetes mellitus; TAG: triacylglycerol; TC: total cholesterol.

Fig. 1. Flowchart of search strategy used in the systematic review. The relevant number of papers at each step is given.
3.1. Antidementia 
Tables 1 and 2 shows 25 studies that suggested direct neuroprotective and cognition-enhancing 
effects of berberine. Potential benefits were demonstrated in 16 nondiabetic studies (Table 1) and in 
9 studies using diabetic models (Table 2). In nondiabetic models, berberine protected learning and 
memory in heavy metal-induced AD [28], Aβ-induced memory deficits model [34], familial AD 
models [29,35,38] and D-galactose-induced brain damage [40,145]. In the rat VaD model induced 
by chronic cerebral hypoperfusion, berberine protected hippocampal calyculin A1 (CA1) neurons 
and prevented memory deficit [27]. Mechanistically, berberine reduced oxidative stress in the brain 
by increasing the levels of antioxidants, including glutathione, glutathione peroxidase and 
superoxide dismutase (SOD) [28,35,37], reduced AChE expression levels [28] and AChE activity at 
as low as 0.44–6 µmol/L half maximal inhibitory concentration [30,33,36,41] and uncompetitively 
inhibited indoleamine 2,3-dioxygenase [32], the first rate-limiting enzyme of kynurenine pathway, 
thereby potentially reducing the accumulation of neurotoxic metabolites involved in AD 
pathogenesis [146–148]. Berberine reduced Aβ generation in Swedish mutant amyloid precursor 
(APP)-expressing cells [31] and suppressed the Aβ-induced inflammatory response in microglia 
[42]. In addition, berberine reduced hyperphosphorylation of tau and APP [29,39], possibly through 
inactivation of GSK3β via Akt signaling [29].
On the other hand, growing evidence suggests that berberine prevents dementia associated with 
diabetes [43–55,61–63] (Table 2). Berberine inhibited apoptosis in the hippocampus and cerebral 
cortex, suppressed anxiety and restored recognition memory in the sporadic AD model induced by 
intracerebroventricular injection of streptozotocin (STZ), possibly via reduction of AChE activity 
[44,51]. It also suppressed hippocampal inflammation, protected neurons and synapses and 
ameliorated cognitive impairment through improved lipid metabolism in leptin receptor-deficient 
(db/db) diabetic mice [49]. In STZ-induced diabetic model, berberine alleviated cognitive 
dysfunctions [44,45,49,53,55,62] by protecting hippocampal CA1 neurons [55,62] and restoring 
hippocampal short-term and long-term plasticity [54,55], reducing oxidative stress [55], inhibiting 
brain inflammation [51,53], suppressing Aβ generation via inhibition of the phosphoinositide 3-
kinase (PI3K)/Akt/GSK3β pathway [51] and reducing diabetes-associated AChE induction in the 
hippocampus and cortex [45]. In the STZ-induced VaD model in rats, berberine enhanced nitric 
oxide (NO) generation and blood flow in the cerebral artery, reduced oxidative stress and alleviated 
memory impairment, possibly via suppression of hyperglycemia-induced ectopic expression of 
miR-133a [44]. Of note, berberine supplementation restored glucose transporter levels and insulin 
signaling in the brain [50], suggesting that modulation of glucose metabolism in the brain may 
underlie the neuroprotective effect of berberine. Moreover, berberine activated 5'-adenosine 
monophosphate-activated protein kinase (AMPK), a key regulator of cellular energy homeostasis, 
restored mitochondrial membrane potential in neurons under high glucose (HG) stress [63] and 
protected neurons from glucose-induced oxidative stress in vitro [37,47], suggesting that berberine 
could alleviate neuronal damages under hyperglycemia.
3.2. Prevention of MetS
3.2.1. Pancreatic dysfunction
Both clinical and preclinical studies (Table 3) have shown that berberine could alleviate insulin 
resistance and reduce blood glucose [60,72,75,124,139,140], which is likely due to the protection of 
pancreatic β-cells [56,137,140] and restoration of insulin secretion [56,139,142]. Molecular 
mechanisms underlying berberine’s pancreatic protection include modulation of anti-apoptotic Bax 
and pro-apoptotic Bcl-2 expression levels [138], activation of AMPK [139,142], restoration of 
sirtuin 1 (SIRT1) [141] and induction of uncoupling protein 2 (UCP2) [142]. SIRT1 is a 
nicotinamide adenine dinucleotide+-dependent histone deacetylase that plays crucial roles in the 
protection of pancreatic β-cells against inflammation and oxidative stress [149]; UCP2 regulates 
redox homeostasis and insulin expression in β-cells. Thus, it is likely that berberine promotes the 
survival of β-cells through several molecular pathways.
3.2.2. Vascular dysfunction
In STZ-induced diabetic models (Table 4), berberine reduced total cholesterol, triglyceride and 
LDL-C, while increasing high-density lipoprotein cholesterol (HDL-C) 
[58,59,62,75,105,108,120,129,141]. In ApoE-/- mice fed with high-fat diet (HFD), a model for 
Western diet-induced atherosclerosis, berberine significantly attenuated the development of severe 
cardiovascular symptoms [130]. Berberine has also been shown to reduce total cholesterol and 
LDL-C in clinical trials [23,60]. In studies in vitro, berberine alleviated palmitate-induced 
endothelial dysfunction via upregulation of endothelial nitric oxide synthase (eNOS) and 
downregulation of nicotinamide adenine dinucleotide phosphate oxidase 4 (NOX4) [114], an 
enzyme involved in age-associated cardiovascular dysfunction via oxidative stress and 
inflammation [150]; it also inhibited HG-potentiated platelet aggregation [134], suppressed HG-
induced endothelial dysfunction and restored NO generation possibly via suppressing ectopic miR-
133a expression and restoring peroxisome proliferator-activated receptor (PPAR) γ and AMPK 
signaling [44,121,123,125,126]. In another study, it reduced oxidized LDL-induced inflammatory 
responses in macrophages via AMPK activation and nuclear factor (NF)-B inhibition [135]. In 
addition, berberine protected cardiomyocytes from HG-induced damage and ischemia-reperfusion 
via enhancement of AMPK [116,120,124,132], PPARα [115] and PI3K-Akt-eNOS anti-apoptotic 
signaling pathways [116]. Berberine also attenuated cardiac fibrosis, possibly by reducing insulin-
like growth factor (IGF)-1 receptor expression in cardiac fibroblasts [129], and enhanced lipid 
metabolism in cardiomyocytes, possibly via protein kinase C inhibition [119,127]; it also 
suppressed cardiac arrhythmia by modulating K+ and Ca2+ [110,113]. Furthermore, berberine may 
alleviate vascular dysfunction in diabetes by acting on adipose tissues. Berberine reduced body 
weight in HFD-fed mice [131,136], and induced fibroblast growth factor 21 (FGF21) and brain and 
muscle aryl hydrocarbon receptor nuclear translocator protein (Arnt)-like 1 expression in brown 
adipocytes in vivo and in vitro [136], suggesting that berberine could modulate lipid metabolism in 
adipose tissues. Berberine also blocked adipogenesis in vitro [117,118], suppressed inflammatory 
(M1) macrophage polarization and aberrant extracellular matrix (ECM) deposition in adipose tissue 
of HFD-induced insulin-resistance model mice [128,131]. In another study, it alleviated visceral 
white adipose tissue insulin resistance, possibly via sterol regulatory element-binding proteins 
(SREBPs) and PPARs [112]. Thus, berberine could alleviate diabetes-associated vascular 
dysfunctions via multiple pathways.
3.2.3. Liver dysfunction 
As shown in Table 5, berberine alleviated liver damage in STZ- and HFD-induced diabetic models 
[43,95,97,105,107,108], as well as in alloxan-induced diabetic model [98]. Treatment with 
berberine improved carbohydrate metabolism, and reduced oxidative stress, lipid peroxidation, 
inflammation and apoptotic cell death in the liver in STZ-induced diabetic model [43,99,107]. 
Similarly, in HFD-induced obesity models, insulin receptor and insulin receptor substrate (IRS)-1 
induction, reduced inflammation [108] and hepatic mitochondrial protection were observed [101]. 
There may be several mechanisms that support these outcomes: berberine could improve glucose 
metabolism in the liver by stimulating glucose uptake [109],  enhance glycolysis by restoring the 
expression and activity of the rate-limiting glycolytic enzyme [103], while suppressing 
gluconeogenic enzymes [102,109], enhance lipid metabolism in the liver by modulating metabolic 
regulators such as human liver X receptor α (LXRα), SREBPs and PPARα [95], and induce brown-
like gene expression and high energy expenditure via FGF21 and SIRT1 signaling activation [106]. 
Furthermore, berberine could relieve hepatic inflammation possibly via AChE inhibition and 
restoration of ACh receptor-mediated anti-inflammatory signaling [104]. Thus, berberine has 
treatment effects that should combat diabetes-associated liver dysfunction and non-alcoholic fatty 
liver disease (NAFLD).
3.2.4. Kidney dysfunction
As shown in Table 6, berberine ameliorated renal inflammation and injury in diabetic models 
[79,83,85,86,90,96]. Underlying mechanisms include inhibition of kidney fibrosis via tumor growth 
factor (TGF)- signaling suppression and Nrf2 activity enhancement [76,77,80,82,86,91,93,144], 
suppression of HG-induced mesangial cell proliferation and hypertrophy via suppression of NF-B 
and AP-1 [81,84,90], and attenuation of ECM accumulation [87], possibly by restoring β-arrestin 
[88] and E prostanoid receptor 4 (EP4)-Gαs-cAMP signaling pathway [83,85]. In addition, 
berberine directly protected podocytes from HG-induced injury in vitro [23,94], possibly by 
inhibiting podocyte apoptosis via AMPK-dependent autophagy induction [92]. 
3.2.5. Intestinal metabolism, gut dysbiosis and systemic inflammation
As shown in Table 7, berberine significantly affected intestinal microbiota and metabolism. Not 
only did berberine modulate intestinal glucose uptake by directly inhibiting digestion of 
disaccharides [68,69], but modulation of the gut microbiome may underlie these beneficial effects. 
For example, berberine increased Verrucomicrobia, which was associated with attenuation of 
atherosclerosis [130], increased Akkermansia and restored intestinal barrier integrity [71,74], and 
restored short-chain fatty acid-producing Bacteroidetes in obese rodents [75]. It is postulated that 
berberine-mediated changes of gut microbiota, particularly the increase of short-chain fatty acid-
producing bacteria [73,75], may contribute to the alleviation of inflammation, insulin resistance and 
obesity [70,74]. Berberine also reduced the levels of plasma endotoxin and systemic inflammation 
in HFD-induced obesity model, possibly by reducing Escherichia coli and increasing Lactobacillus 
[108]. 
3.2.6. Diabetic retinopathy
As shown in Table 8, berberine protected retinal Müller cells from HG- and LDL-induced damage 
via enhancing AMPK signaling [65,66] and prevented retinal endothelial injuries induced by HG-
activated leukocytes [64].
3.2.7. Diabetic neuropathy
Berberine ameliorated diabetic neuropathy [61–63] (Table 9), indicating the protection of the 
peripheral nervous system.
3.2.8. Additional evidence
As shown in Table 10, both clinical and preclinical studies demonstrated that berberine can 
effectively restore normal glucose and lipid levels in the blood [22,58–60,67,78,122,133]. 
Suggested underlying mechanisms include enhanced glucose uptake [100,111,143], mitochondrial 
complex I inhibition [57] and AMPK signaling enhancement [57,89]. 
4. Discussion
4.1. Direct evidence supporting berberine’s antidementia effects 
AD is a metabolic disease with diabetes-associated molecular and biochemical features; 
dysfunctional insulin signaling in the brain may account for the structural and functional 
abnormalities in AD [151]. The expression levels of IGFs are significantly reduced in the AD brain, 
which was associated with reduced levels of IRS, IRS-associated PI3K and downstream 
serine/threonine-specific protein kinase Akt, as well as increased GSK3β activity [16]. As a master 
regulator of cellular energy metabolism, GSK3β is highly expressed in the adult hippocampus, 
particularly with age [152]. Its multiple functions include regulation of neural plasticity via 
neurogenesis, migration, axonal growth and synaptic plasticity [153]. The PI3K/Akt/GSK3β 
pathway plays crucial roles in neuroprotection and synaptic plasticity under various physiological 
and pathological circumstances [154,155]. However, abnormally active GSK3β contributes to brain 
disorders including impairments in mood regulation, cognitive task performance [156] and 
hippocampal neurogenesis [157]. Importantly, tau protein is one of the targets of GSK3β [158], and 
the PI3K/Akt/GSK3β pathway may play a key role in AD pathogenesis via enhanced 
phosphorylation of tau [158]. These data suggest that dysfunctional glucose metabolism may 
underlie AD development [16]. In fact, experimental diabetes induced by STZ causes cholinergic 
dysfunction and memory impairment [159]. Furthermore, intracerebral administration of STZ led to 
features characteristic of AD, including cognitive impairment and ACh homeostasis disturbances 
[160], which could be alleviated by insulin sensitizers [15,161]. 
Our literature survey indicated that berberine directly protects the brain cells against damages 
associated with dementia [27,29,32,34,39], possibly via antioxidative and anti-inflammatory effects 
[28,35,37,42], and also by reducing A levels [31,38]. Berberine was able to promote cognitive 
functions [38,40], through enhancing cholinergic neurotransmission [30,33,36,41]. In addition, 
berberine alleviated diabetes-associated cognitive impairment [44,45,48,49,51–55], possibly via the 
restoration of insulin signaling [50,51] and reduction of oxidative stress and inflammation 
[43,46,47] in the brain. Although bioavailability of berberine is relatively low, it crosses the blood 
brain barrier and stably distributes in the brain tissue, compared to other organs [162], suggesting 
that berberine could prevent dementia through direct actions in the brain. As a whole, berberine 
could protect brain functions via a number of mechanisms: neuroprotection [55,62], reducing 
oxidative stress [28,35,37,43], suppressing brain inflammation [51,53], reducing the generation of 
Aβ, hyperphosphorylated tau and APP [29,31,39,146], enhancing ACh signaling 
[28,30,33,36,41,45], and possibly reducing the accumulation of neurotoxic metabolites [32], 
suggesting that berberine is an effective therapy against dementia including AD and VaD.
4.2. Antidementia effects of berberine via prevention of diabetes and comorbidities: an indirect 
mechanism
Evidence suggests strong associations between dementia and diabetes [7,8,15,16], which indicates 
that the risk of developing dementia could be reduced by a successful diabetes intervention. 
Berberine is a promising antidiabetic agent, as reported in previous review articles [20,21,24,163]. 
In the present work, we have updated how berberine acts against diabetes and its associated 
complications; we also discuss the potential of berberine as a treatment for diabetes-associated 
dementia.
4.2.1. Protection of pancreas 
T2DM is characterized by hyperglycemia, associated with insulin resistance and insufficient insulin 
secretion due to pancreatic β-cell dysfunction. Our literature survey revealed that berberine protects 
pancreatic cells and restores insulin secretion by β-cells [56,137–142]. Brain insulin resistance is a 
key feature of AD and related dementias, and evidence suggesting the link between systemic and 
brain insulin resistance is growing [164,165]. Thus, berberine may prevent dementia development 
by restoring pancreas functions and systemic insulin signaling.
4.2.2. Vascular protection 
VaD is the second common form of dementia [166]. Although there are controversies surrounding 
the etiology of VaD, cerebral small vessel disease, associated with the breakdown of blood-brain 
barrier and perivascular inflammation, is likely the most common cause [166,167]. The risk factors 
include dyslipidemia, hypertension and cardiovascular dysfunction [166]. High levels of LDL-C 
and low levels of HDL-C increase the risk for carotid atherosclerosis and coronary artery disease, 
which may result in cerebral hypoperfusion or embolism, leading to cognitive dysfunctions 
[166,168]. In addition, cardiovascular disease-associated oxidative stress and lipid peroxidation, 
due to low levels of antioxidants, are thought to cause damage to brain cells [166,169,170]. 
Dyslipidemia and hypertension, associated with obesity and insulin resistance, are often present in 
the prediabetic period of T2DM, which may account for the comorbidity of cardiovascular disease 
and diabetes [171,172]. T2DM dyslipidemia is characterized by increased triglycerides and LDL-C 
and reduced HDL-C levels [173,174]. Evidence suggests that cholesterol-lowering therapy reduces 
cardiovascular risk in diabetic patients [174,175]; however, low HDL-C likely contributes to 
diabetes as well as cardiovascular disease [173]. Thus, lowering total cholesterol while restoring 
HDL-C would be most beneficial for treating diabetes-associated cardiovascular diseases and VaD. 
On the other hand, studies have suggested that impaired endothelial dysfunctions and platelet 
hyperaggregation, causing microvasculature injuries, are the main causes of increased morbidity 
and mortality of T2DM [176]. Impaired eNOS activity and hypercoagulable states associated with 
atherosclerosis and vascular dysfunction are observed in the vascular system of diabetes and 
associated MetS [177,178]. In addition, altered glucose metabolism and glucose overload in 
cardiomyocytes promote oxidative stress and accumulation of advanced glycation end-products, 
subsequently causing apoptosis and cardiac dysfunction [179,180]. Furthermore, pro- and anti-
inflammatory mediators released from perivascular adipose tissue are involved in the development 
of atherosclerosis [181], suggesting that adipocytes may play a key role in diabetes-associated 
cardiovascular dysfunctions. 
The results demonstrated that berberine could protect cardiovascular functions by reducing the risk 
of hypertension [123,126] and coagulation [134], attenuating cardiac hypertrophy [115,129,132] 
and cardiac arrhythmias [110,113], and inhibiting potential cardiovascular damages associated with 
dyslipidemia [74,114,116,119–121,124,125,130,135,136]. In addition, berberine reduced obesity 
and cardiovascular risk at least in part via modulating adipocyte populations and inflammatory state 
in the adipose tissues [112,117,118,128,131]. Taken together, berberine could promote vascular 
functions, thereby preventing the development of VaD.
4.2.3. Liver protection 
The liver plays a vital role in energy metabolism. Hepatic insulin signaling is essential for the 
maintenance of carbohydrate and lipid homeostasis, and the liver plays a major role in the 
development of insulin resistance and T2DM [182]. NAFLD and T2DM are common conditions 
associated with insulin resistance and vascular dysfunctions, and NAFLD prevalence is high in 
prediabetic and obese populations [182–184]. Evidence suggests the link between T2DM or 
NAFLD and insulin resistance in the brain [185,186], and that hepatic ceramide, a neurotoxin that 
causes insulin resistance, may mediate brain insulin resistance and neurodegeneration in T2DM and 
NAFLD [187]. In fact, NAFLD induces signs of AD in wild-type mice and accelerates pathological 
signs of dementia in an AD model [188]. Thus, the liver could be an important target in the 
prevention of AD and MetS-associated dementia. 
The results indicated that berberine protects liver functions [102,103,105,108] through restoring 
glucose and lipid metabolism [95,101,104–106,109] and suppressing inflammation and oxidative 
stress [43,97,98,104,107]. Collectively, berberine could prevent dementia through the restoration of 
liver functions.
4.2.4. Kidney protection 
Diabetic nephropathy is a major complication and a common cause for chronic kidney disease 
(CKD) [189], which is significantly associated with cognitive impairment [190,191]. Between 16% 
and 38% of dialysis patients have cognitive impairment, which is approximately threefold higher 
than age-matched controls [192]; VaD seems more prominent in CKD than other types of 
dementias, such as AD [193]. Dialysis patients tend to have reduced total brain and subcortical 
volumes and perform poorly in attention/information processing speed and executive function [194]. 
Glomerular mesangial cell hypertrophy and podocyte loss are the major pathological changes of 
diabetic nephropathy [195], and injuries to podocytes associated with dysregulation of AMPK play 
a key role in diabetic nephropathy [195]. Indeed, deficient autophagy caused by AMPK 
dysregulation can induce podocyte loss and glomerulosclerosis [196], pointing to the importance of 
AMPK signaling in treating diabetic nephropathy and associated cognitive impairment. 
This study revealed that berberine prevents diabetic nephropathy [79,83,85,86,90,96]. Potential 
mechanisms include podocyte protection [92,94] via AMPK activation [92], and inhibition of renal 
fibrosis and inflammation [76,77,80–82,84,86,91,93,144] via TGF-β signaling suppression 
[80,82,84,86,91,93,144]. Considering that TGF-β promotes kidney cell injury via inhibition of 
AMPK [197], it is probable that berberine ameliorated kidney fibrosis by counteracting TGF-β 
signaling by restoring AMPK activity. Collectively, berberine could prevent diabetic nephropathy 
via suppression of hypertrophy and podocyte protection, thereby alleviating cognitive impairment 
associated with kidney dysfunction.
4.2.5. Restoration of gut microbiota and intestinal metabolism 
Among 100 trillion micro-organisms residing in human body, the vast majority are in the intestinal 
tract [198]. Growing evidence indicates that a critical role of the gut microbiota is as a host 
metabolism regulator [199], and the imbalance of gut microbiota (gut dysbiosis) has been linked to 
various metabolic disorders including diabetes [200,201]. Changes in the intestinal ecosystem could 
alter intestinal permeability, cause inflammation and modulate bile acid metabolism, short-chain 
fatty acids and other metabolites, contributing to insulin resistance [202] and progression of 
diabetes-associated conditions [203,204]. In fact, links between the gut microbiota and NAFLD 
[205], cardiovascular disease [206] or CKD have been suggested [207]. Furthermore, the intestinal 
microbiota likely takes part in bidirectional communication between the gut and the brain [208]. 
Thus, gut microbiota provides a promising therapeutic target to alleviate diabetes-associated 
dementia. 
Our literature review indicated that berberine influences body metabolism and suppresses systemic 
inflammation via modulation of gut microbiota [70,74,75,108,130]. Of note, berberine-containing 
plants, such as Coptis and Phellodendron spp., have been used traditionally to treat diarrhea, as well 
as to promote intestinal health [209], and berberine’s antimicrobial activity against various 
pathogenic bacteria is well known [210]. Due to poor absorption of berberine, it is reasonable to 
speculate that antidiabetic action of berberine is at least in part mediated via effects on the gut 
microbiota [210].
4.2.6. Retinal protection
Evidence suggests that the status of retinal neuronal structure and vasculature can reflect that of the 
cerebral nervous system [211]. Our literature survey revealed that berberine could prevent diabetic 
retinopathy [64–66]. Although the mechanistic link between retinal injuries and cognitive 
dysfunction is not clear, these data support that berberine could prevent diabetes-associated 
damages to the neuronal network in the central nervous system, including retina.
4.2.7. Enhancing glucose and lipid metabolism
In addition to preventing diabetes-associated tissue damages, berberine may reduce the risk of MetS 
development by enhancing glucose and lipid metabolism. However, despite berberine’s well-
established antihyperglycemic and antihyperlipidemic activities, the underlying molecular 
mechanisms are less clear. One suggested mechanism is that berberine lowers blood glucose by 
enhancing AMPK activity in peripheral tissues [89, 212]. AMPK is a serine/threonine kinase that is 
activated in response to adenosine triphosphate (ATP) depletion; its action is to restore cellular ATP 
levels and energy supply, acting as an energy sensor and a metabolic master regulator [213]. 
Enhanced AMPK activity, upon berberine-treatment, has been observed in several studies using 
diabetic animal models [63,65,102,128] as well as in vitro models [57,65,66,114,128,132,135]. 
However, it is not clear whether the glucose-lowering effect is indeed mediated by AMPK 
activation [57]. Recent studies suggest that berberine’s glucose-lowering effects could operate 
through a variety of mechanisms, including: enhanced cellular glucose uptake and consumption 
[57,59,100,111,143] via p38 MAP kinase and ERK signaling [111]; protein-tyrosine phosphatase 
1B (PTP1B) inhibition, thereby mimicking insulin signaling [100,133]; and insulin receptor 
sensitization to low-dose insulin [22]. However, this mechanism is likely independent of AMPK 
[57,111]. In addition, berberine is a potent mitochondrial complex I inhibitor and can affect glucose 
consumption through reduction of ATP generation from mitochondrial oxidative phosphorylation 
and consequent enhancement of glycolytic activity [57]. Thus, berberine might act as 
antihyperglycemic, through multiple targets including mitochondrial complex I, while AMPK 
activation might benefit different aspects of diabetic complications, such as suppression of 
inflammation [135] and hepatic gluconeogenesis [102]. On the other hand, the antihyperlipidemic 
activity of berberine could be explained by induction of brown adipocytes via FGF21 signaling 
[106,136,214], possibly through AMPK [136].
4.3. Limitations and future perspectives
In summary, evidence from numerous studies supports the effectiveness of berberine as a dementia 
intervention via direct neuroprotection in the brain as well as indirect mechanisms through the 
prevention of diabetes-associated comorbidities (Fig. 2). Growing evidence suggests that both AD 
and VaD are associated with diabetes [7,8,15,16,215,216], and the risk of dementia development 
could be reduced by successful intervention of diabetes and its comorbidities [13,215,217]. As 
summarized in previous review articles, berberine is a promising antidiabetic agent [20,21,24,163], 
and preclinical evidence suggests that berberine has neuroprotective effects [25,218–221]. Here, we 
collectively evaluated the effectiveness of berberine as a treatment for diabetes-associated dementia 
by two database searches (Fig. 1). The advantage of this study is that it clarified direct and indirect 
evidence by categorizing the publications into three groups: antidementia effects that has no 
obvious association with diabetes (Table 1), effects on diabetes-associated dementia (Table 2) and 
antidiabetic effects (Tables 3 to 10). The limitations of the study include the fact that most of the 
articles reviewed in this report are preclinical studies using in vivo and/or in vitro models, thus 
future research must focus on clinical significance. In addition, it is unknown whether berberine, as 
a constituent of traditional medicine, rather than as an isolate, could exert the same effectiveness. 
Berberine is a natural alkaloid found in various medicinal plant species [36,222–229] (Table 11). 
These medicinal plants could be useful in the prevention of dementia associated with metabolic 
disorders. Using locally available plants may have advantages over isolates, reducing the cost and 
possibly providing additional therapeutic and nutritional benefits derived from the plants. In fact, 
some of those plants, including B. vulgaris, Coptis spp. and P. amurense have been used in 
traditional medicines to treat cardiovascular diseases, diabetes and dementia [230–233]. However, 
those plants contain berberine at different levels, and the variability of berberine contents within the 
same species, depending on the geographical origins and plant parts used, is nonnegligible 
[222,228]. Furthermore, those plants and their extracts contain numerous other constituents, which 
might produce synergistic effects, either enhancing or reducing the efficacy of berberine. Further 
research is needed to assess the effectiveness and safety of berberine-containing medicinal plants in 
the prevention of dementia associated with metabolic dysfunctions. 
Fig. 2. Potential mechanisms underlying therapeutic effects of berberine to treat and prevent dementia. Berberine enhances cognition via direct actions in the 
brain, as well as indirectly via alleviating diabetes and associated complications. Notable berberine actions are indicated in red. AChE: acetylcholinesterase; 
IDO: indoleamine 2, 3-dioxygenase.
Table 11. Berberine contents in medicinal plants.
Species Part Content (mg/g) Extraction method Reference
Root 121.8 EtOH/ultrasonicBerberis aristata DC.
Stem 102.3 EtOH/ultrasonic
[222]
Root 78.1 EtOH/ultrasonicBerberis asiatica Roxb. ex DC.
Stem 29.9 EtOH/ultrasonic
[222]
Root 106 EtOH/ultrasonicBerberis chitria Buch-Ham. ex Lindl.
Stem 2 EtOH/ultrasonic
[222]
Root 11.2 EtOH/ultrasonicBerberis jaeschkeana C.K.Schneid.
Stem 6.4 EtOH/ultrasonic
[222]
Root 144.9 EtOH/ultrasonicBerberis koehneana C.K.Schneid.
Stem 29.5 EtOH/ultrasonic
[222]
Root 172.8 EtOH/ultrasonicBerberis lycium Royle
Stem 18.2 EtOH/ultrasonic
[222]
Root 24.1 EtOH/ultrasonicBerberis petiolaris Wall. ex G.Don
Stem 5.2 EtOH/ultrasonic
[222]
Root 43.8 EtOH/ultrasonicBerberis pseudumbellata R.Parker
Stem 14.6 EtOH/ultrasonic
[222]
Berberis thunbergii DC. NA 6.36 MeOH [223]
Berberis vulgaris L. Root 7.14–13.8 MeOH [224]
Coptis chinensis Franch. Rhizome 65.2 1% HCl in MeOH/ultrasonic [225]
Coptis deltoidea C.Y. Cheng & P.K. Hsiao Rhizome 47.2 1% HCl in MeOH/ultrasonic [225]
Coptis omeiensis (C. Chen) C.Y. Cheng Rhizome 62.2 1% HCl in MeOH/ultrasonic [225]
Coptis teeta Wall. Rhizome 92.6 1% HCl in MeOH/ultrasonic [225]
Chelidonium majus L. 5.37 MeOH [225]
Root 24.4 Acetonitrile:water:phosphoric 
acid (70:30:0.1, v:v:v)
[226]
Root 37.8 MeOH/reflux [227]
Hydrastis canadensis L.
Rhizome 46.2 MeOH/reflux [227]
Mahonia aquifolium (Pursh) Nutt. 3.34 MeOH [223]
Mahonia leschenaultii (Wall. ex Wight & Arn.) Takeda Root 62.2 EtOH/ultrasonic [228]
Mahonia napaulensis DC. Root 86.6 EtOH/ultrasonic [227]
Phellodendron amurense Rupr. Stem 17.8–47.0 75% EtOH/ultrasonic [229]
Phellodendron chinense C.K. Schneid. Bark 269.7 70% EtOH/reflux [36]
EtOH: ethanol; MeOH: methanol; NA: no information available.
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